

CURRICULUM VITAE

KENNETH C. LASSETER, M.D.

Date of Birth: August 12, 1942

Place of Birth: Jacksonville, Florida

Marital Status: Married, three children
Kenneth C. 1967, Susan I. 1967,
Frank L. 1972

Home Address: 417 Laguna Avenue
Key Largo, Florida 33037

6995 Gleneagle Drive
Miami Lakes, FL 33014

Office Address: Clinical Pharmacology of Miami, Inc.
550 West 84th Street
Miami, FL 33014-3616

Office Telephone: (305) 817-2900
(305) 817-8234 Fax
(305) 525-2805 Mobile

E-Mail Address: klasseter@clinpharmmmiami.com

Military Status: Captain M.C., U.S.A.R.
Honorable Discharge
January 24, 1983

Education: B.S. Degree - 1963,
Stetson University,
Deland, Florida

M.D. Degree - 1967,
University of Florida School of Medicine,
Gainesville, Florida

Post Graduate Education:

Straight Medical Internship,
University of Kentucky Medical Center,
Lexington, Kentucky, 1967 – 1968

Resident in Medicine,
University of Kentucky Medical Center,
Lexington, Kentucky, 1968 - 1969

Postdoctoral Fellow in Cardiology,
University of Kentucky Medical Center,
Lexington, Kentucky, 1969 - 1970

Postdoctoral Fellow in Clinical
Pharmacology and Cardiology,
University of Miami School of Medicine,
Miami, Florida, 1970 - 1972

Medical Licensure:

State of Kentucky, 1969
License Number 14912

State of Florida, 1970
License Number 15214

DEA Registration
AL0 XXXXXX (available on request)

Board Certification:

Diplomate, American Board of Clinical
Pharmacology, Certificate Number 92116

Honors and Awards:

Kappa Mu Epsilon-1960
Honorary Mathematics Society

Gamma Sigma Epsilon-1961
Honorary Chemistry Society

Faculty Research Award-1967

AOA Research Award-1967

Sigma Xi-1967

Interstate Postgraduate Medical
Association Research Award-1974

Listed in International Who's Who in Education-1979

Listed in American Men and Women in Science-1979

Listed in Personalities of America-1981

Listed in Who's Who in the South and Southwest, 18th Edition-1983; 19th Edition-1985; 20th Edition-1988; 21st Edition-1989; 22nd Edition-1991; 23rd Edition-1993.

Listed in American Men and Women of Science 16th Edition 1986; 17th Edition-1989

Listed in Who's Who of Emerging Leaders in America-1987

Listed in Who's Who in Florida-1988

Listed in Who's Who in America, 47th Edition-1992; 48th Edition-1994; 49th Edition-1995; 50th Edition-1996; 51st Edition-1997; 52nd Edition-1998, 53rd Edition-1999, 54th Edition-2000, 55th Edition-2001, 56th Edition-2002, 57th Edition-2003

Listed in Who's Who in Medicine and Healthcare, 1st Edition; 1997-1998

Visiting Distinguished Alumnus, Department of Chemistry, Stetson University, March 13-14, 1997

Listed in Who's Who in the 21st Century, International Biographical Center, Cambridge, CB2 3QP, England, 2001

Listed in Who's Who in the World, 21st Edition, Marquis Who's Who Publishers, New Providence, NJ, 2003.

Listed in "Guide to America's Top Physicians," 2004-2005 Edition, Consumer's Research Council of America, Washington, DC.

Academic Appointments:

Assistant Professor of Pharmacology and Medicine, University of Miami, School of Medicine, Miami, Florida 1971 - 1974.

Associate Professor of Pharmacology and Medicine, University of Miami School of Medicine, Miami, Florida 1974 - 1981.

Adjunct Associate Professor of Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, 1981 - present.

Adjunct Assistant Professor of Pharmacology, Barry University, Miami Shores, Florida, 1986 - 1987.

Previous Positions:

Vice-President and Medical Director, Clinical Pharmacology Associates, 2060 N.W. 22nd Avenue, Miami, Florida 33142. 1981 - 2003.

Executive Medical Director, SFBC International, Inc., 11190 Biscayne Blvd, Miami, Florida 33181. 2003-2006.

Current Position:

Vice President and Medical Director, Clinical Pharmacology of Miami, Inc., 550 West 84th Street, Miami, Florida 33014-3616. 2006-present.

Current Teaching Responsibilities:

Frequent lecturer at local hospital postgraduate courses and programs and at Medical programs.

Past Teaching Responsibilities:

1. Advisor and thesis committee chairman for Charles Meier who received Ph.D. degree, 1977.
2. Advisor and thesis committee chairman for Robert G. Zoble who received Ph.D. degree, 1978.
3. Lecturer and coordinator of cardiovascular section of Mechanisms of Disease Course for sophomore medical students 1973 - 1979.
4. Lecturer in Pharmacology Mechanisms Course (M600) for freshman medical students, University of Miami 1971-1988.
5. Lecturer in Pharmacology Core Course (M601) for sophomore medical students, University of Miami 1971-1985.
6. Attending physician for Clinical Pharmacology section of Cardiology Senior Medical Student Elective Program, 1975 - 1980.
7. Lecturer in Pharmacology Course for Ph.D. to M.D. Program and preceptor for Ph.D. to M.D. students 1975-1985.

8. Attending physician for Clinical Pharmacology consultation rounds for house staff and fellows at Jackson Memorial Hospital and for Clinical Pharmacology Elective Program for senior medical students at the University of Miami, School of Medicine 1972-1990

Past Research Activities:

1. Studies of the mechanisms of action of antiarrhythmic agents using intracellular electrophysiologic recording techniques investigating the non-action potential duration dependent lengthening of effective refractory period. This is probably the only electrophysiologic effect shared in common by all agents with antiarrhythmic activity and appears to be related to alteration in the kinetics of reactivation of rapid sodium current.
2. Electrophysiologic studies of the kinetics of sodium channel inactivation employed phase plane analysis for estimation intracellular sodium activity.

Current Research Activities:

1. Principal Investigator of approximately 1200 clinical studies (over past 38years) of the safety and efficacy and mechanisms of action of Phase I, II and III drugs as well as bioavailability and pharmacokinetic studies in normal subjects and in special populations. Numerous clinical studies have been successfully audited by sponsoring institution audit teams and by Food and Drug Administration Audit Teams. Virtually all studies have been conducted under auspices of active IND applications and approximately 60 successful NDA's have contained data generated by these studies. These include: acrovastine, alendronate, amiloride, amrinone, arbutamine, atenolol, benzazepril, candesartan cilexetil, carteolol, caspofungin, ciprofloxacin, dofetilide, enalapril, encainide, eplerenone, recombinant erythropoietin, etodolac, famotidine, felodipine, finasteride, flecanide, fosinopril, galantamine, grepafloxacin, indapamide, irbesartan, leucovorin, lisinopril, losartan, meropenem, milrinone, moexepiril, montelukast, nefazodone, nimodipine, nisoldipine, nitroprusside, nizatidine, oxaprozin, penbutalol, pinacidil, piperacillin, piroxicam, prazosin, ramipril, 13-cis retinoic acid, rofecoxib, sinemet CR, sirolimus, sitagliptin, sulindac, tegaserod, timolol, terazocin, tocanide, trandolapril, valsartan, venlafaxin, zafirlukast, zolmitriptan and zolpidem.

Committee Responsibilities:

1. Member of Curriculum Coordinating Committee, University of Miami. 1973 - 1979.
2. Member of Anesthesiology Search Committee, University of Miami. 1974 - 1975.
3. Member of Membership Committee, American College of Clinical Pharmacology. 1973 - 1974.
4. Member of Promotion and Tenure Committee, University of Miami. 1976 - 1979.
5. Coordinator and member of committee for the Cardiovascular Section of the Mechanisms of Disease Course, University of Miami. 1973 - 1978.
6. Member of Pharmacy and Therapeutics Committee of Jackson Memorial Hospital. 1979 - 1981.
7. Member of Research Committee of Greater Miami Heart Association. 1975 - 1981.
8. Member of Florida Medicaid Drug Utilization Review Committee. 1975 - 1981.
9. Member of Veterans Hospital Committee for the Protection of Human Subjects in Research. 1979 - 1982.
10. Member of Executive Committee for Clinical Pharmacology of ASPET. 1977 - 1983.
11. Consultant and Expert Witness in area of Pharmacology for State of Florida, Department of Professional Regulations. 1982 - 1989.
12. Member of Substance Abuse Curriculum Sub-Committee, University of Miami. 1985 - 1989.
13. Member of Ad Hoc Task Force for the Third Year Curriculum, University of Miami. 1986 - 1989.
14. Member of Pharmacology Test Committee, National Board of Podiatric Medical Examiners, Educational Testing Service, Princeton, New Jersey. 1987 - 1991.
15. Member of Membership Committee of American Society for Clinical Pharmacology and Therapeutics. 1994 - 1997.
16. Member of FIU Biomedical Engineering Advisory Board. 2004-2005.

Editorial Boards:

1. *Current Clinical Pharmacology*, Bentham Scientific Publishers, Ltd. 3 Clover Hill Circle
Ewing Township, NJ 08638-1305 USA. 2005-present.
2. *Advances in Therapy* (Advisory Board), Springer Healthcare Communications, Farside House, Nantwich Road, Tarporley, Cheshire, CW6 9UY, UK. 2009-present.

Memberships:

Sigma Xi	1967
American Heart Association	1968
American College of Physicians	1970
American College of Clinical Pharmacology	1971
American Federation for Clinical Research	1972
New York Academy of Sciences	1973
American Society for Clinical Pharmacology & Therapeutics	1974
American Society for Pharmacology and Experimental Therapeutics	1974
Heart Association of Greater Miami	1976
Dade County Medical Association	1979
Florida Medical Association	1979
Southern Medical Association	1980
American Medical Association	1981
Florida Society of Internal Medicine	1982
Drug Information Association	1983
Southeastern Pharmacology Society	1983
American Society for Microbiology	1985
Associates of Clinical Pharmacology	1987
The American Society of Hypertension	1996
American Association of Pharmaceutical Scientists	2007

BIBLIOGRAPHY

Kenneth C. Lasseter, M.D.

1. Palmer, R.F., **Lasseter, K.C.** and Melvin, S.: Stimulation of Na⁺ and K⁺ activated ATPase by Ouabain. *Arch. Biochem. Biophys.* 113: 629-633, 1967.
2. Surawicz, B. and **Lasseter, K.C.:** Electrocardiogram in pericarditis. *Amer. J. Cardiol.* 26: 471-474, 1970.
3. Surawicz, B. and **Lasseter, K.C.:** Effect of drugs on the electrocardiogram. *Prog. Cardiovasc. Dis.* 13: 26-54, 1970.
4. **Lasseter, K.C.**, Buchanan, J.R. and Yoshonis, K.F.: A mechanism for "False" inhibition of demand pacemakers. *Circulation* 42: 1093-1094, 1970.
5. **Lasseter, K.C.:** Therapy of arrhythmias: Basic considerations. *Med. Clin. N.A.* 55: 435-444, 1971.
6. Palmer, R.F., **Lasseter, K.C.** and McCarthy, J.: Tolbutamide: An inotropic effect on rabbit atria. *Lancet* 1: 604, 1971.
7. Levey, G., Palmer, R.F., **Lasseter, K.C.** and McCarthy, J.: Effect of tolbutamide on adenyl cyclase in rabbit and human heart and contractility of isolated rabbit atria. *J. Clin. Endo. Met.* 33: 371-374, 1971.
8. **Lasseter, K.C.**, Levey, G.S., Palmer, R.F., and McCarthy, J.S.: The effect of sulfonylurea drugs on rabbit myocardial contractility, canine Purkinje fiber automaticity and adenyl cyclase activity from rabbit and human hearts. *J. Clin. Inves.* 51: 2429-2434, 1972.
9. **Lasseter, K.C.**, Palmer, R.F., and Posey, V.A.: Cardiovascular effects of the sulfonylurea drugs. In Controversies in Clinical Pharmacology and Drug Development. Mt. Kisco, N.Y., Futura Publishing Co., pp. 71-81, 1972.
10. Levey, G.S., **Lasseter, K.C.** and Palmer, R.F.: Sulfonylureas and the heart. *Ann. Rev. of Med.*, 25: 69-74, 1974.
11. **Lasseter, K.C.:** Evaluation of antiarrhythmic agents. In F.G. McMahon (Ed.) Principles and Techniques of Human Research and Therapeutics. Volume V: Cardiovascular Drugs, Mt. Kisco, N.Y., Futura Publishing Co. pp. 221-232, 1974.

BIBLIOGRAPHY (Continued)

12. Palmer, R.F. and **Lasseter, K.C.**: Methods for evaluating a new inotropic agent. In F.G. McMahon (Ed.) Principles and Techniques of Human Research and Therapeutics, Volume V: Cardiovascular Drugs, Mt. Kisco, N.Y.; Future Publishing Co., pp. 251-264, 1974.
13. **Lasseter, K.C.** and Palmer, R.F.: Dissecting aneurysm of the aorta as an unusual etiology of asthma: An anatomic pharmacologic correlation. *New England Journal of Medicine*. 291: 87, 1974.
14. Palmer, R.F. and **Lasseter, K.C.**: Drug Therapy: Sodium nitroprusside. *New England Journal of Medicine*. 292: 294-297, 1975.
15. **Lasseter, K.C.**, Cohen, A. and Bock, E.L.: Nefopam HCl interaction study with eight other drugs. *J. Int. Med. Res.* 4: 19-201, 1976.
16. **Lasseter, K.C.**: The hypertension problem and its treatment: *Drug Therapy* 7: 76-84, 1977.
17. **Lasseter, K.C.**: Pharmacologic counterpoint for cardiac arrhythmias. *Drug Update*, May 1977.
18. **Lasseter, K.C.**: The patient with an arrhythmia. *Drug Therapy*, 7: 112-216, 1977.
19. Zoble, R.G., Selevan, J., Currie, E.H. and **Lasseter, K.C.**: Automated on-line determination of membrane responsiveness curves. *IEEE Transactions on Biomedical Engineering*. 25: 481-483, 1979.
20. Batra, V.K., Morrison, J.A., **Lasseter, K.C.** and Joy, V.: Piperacillin Kinetics. *Clinical Pharmacology and Therapeutics* 26: 41-53, 1979.
21. Shapiro, A.G., **Lasseter, K.C.**, Cobiella, A. and Domenzain, M.: Intravaginal administration of 9-Deoxy-9Methylene-16, 16 Dimethyl PGE for cervical dilation prior to suction curettage. *Int. J. Obstetrics and Gynecology*, 20: 132-140, 1982.
22. Chiang, S.T., **Lasseter, K.C.**, Fluck, E.R., Janssen, F.W., Leelavathi, D., and Hubsher, J.A.: Oxaprozen Dose Proportionality. *J. Clinical Pharmacology*, 24: 515-522, 1984.
23. **Lasseter, K.C.**, Shapse, D., Pascutti, V.L., Chiang, S.T. and Dietch, M.W.: Pharmacokinetics of Guanabenz in Patients with Hepatic Impairment. *J. Cardiovascular Pharmacology*, 6: S766-S770, 1984.

BIBLIOGRAPHY (Continued)

24. **Lasseter, K.C.** and Shamblen, E.C.: Comparative Bioavailability and Pharmacokinetics of Uniphyl once daily and Theo-Dur twice daily. In: International Congress and Symposia Series. Number 78: *New Perspectives in Theophylline Therapy*, M. Turner-Warwick and J. Levy (Eds.), Oxford University Press, London, pp. 141-148, 1984.
25. **Lasseter, K.C.**, Shamblen, E.C., Murdoch, A.A., R.G.N., Burkholder, D., Krol, G., Taylor, R.J. and Vanov, S.K.: Steady State Pharmacokinetics of Nitrendipine in Hepatic Insufficiency. *J. Cardiovascular Pharmacology*. 6: S977-S981, 1984.
26. Locniskar, A., **Lasseter, K.C.**, Freeland, G.R., Chiang, S.R., and Greenblatt, D.J.: Pharmacokinetics and Bioavailability of Ciramodol, a New Analgesic. *Drug Develop. Research* 6: 61-66, 1985.
27. Fagan, T.C., Nelson, E.B., **Lasseter, K.C.**, Crook J., Morledge, J., and Conrad, K.: Once and Twice Daily Nitrendipine in Patients with Hypertension and Non-Insulin Dependent Diabetes. *Pharmacotherapy* 6: 128-136, 1986.
28. Harrison, L.I., Smallridge, R.C., **Lasseter, K.C.**, Goldlust, M.B., Shamblen, E.C., Gam, V.W., Chang, S.F. and Kvam, D.C.: Comparative Absorption of Inhaled and Intramuscularly Administered Atropine. *Amer. Rev. Respiratory Dis.* 134: 254-257, 1986.
29. Given, B.D., Vita, N.A., Black, H., Francis C., **Lasseter, K.C.**, and Dzau, V.J.: Chronic Prostaglandin E Analog elicits renal and hormonal compensatory mechanisms in human hypertension. *Hypertension* 8: 489-496, 1986.
30. Callaghan, J.T., Bergstrom, R.F., Rubin, A., Chernish, S., Crabtree, R., Knadler, M.P., Obermeyer, B., Offen, W.W., Schneck, D.W., Aronoff, G. and **Lasseter, K.C.**: A Pharmacokinetic Profile of Nizatidine in Man, (Presented at International Nizatidine Symposium, Vienna, Austria, October 11-12, 1986). *Scandinavian J. Gastroenterology*, 22:9-17 (Suppl 136), 1987.
31. Morledge, J., Brown, R.D., Conradi, E., Giles, T.D., Lewin, A., **Lasseter, K.C.**, Massie, B., Miller, A., Weinberger, M. and Wombolt, D.: Comparative Study of the Effects of Nitrendipine and Hydrochlorothiazide in Hypertensive Patients. *J. Cardiovascular Pharmacology*, 9: S224-S227, 1987.
32. Brater, D.C. and **Lasseter, K.C.**: Profile of Etodolac: Pharmacokinetic evaluation in special populations. *Clinical Rheumatology* 8 (Suppl 1): 25-35, 1989.

BIBLIOGRAPHY (Continued)

33. Frost, R.W., Lettieri, J.T., Krol, G., Shamblen, E.C., and **Lasseter, K.C.**: The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. *Clinical Pharmacology and Therapeutics*. 45: 608-616, 1989.
34. Rittmaster, R.S., Stoner, E., Thompson, D.L., Nance, D. and **Lasseter, K.C.**: Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum Androgens and Androgen Conjugates in normal men. *Journal of Andrology*. 10: 259-262, 1989.
35. Yeh, K.C., August, T.F., Bush, D.F., **Lasseter, K.C.**, Musson, D.G., Schwartz, S., Smith, M. E. and Titus, D.C.: Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. *Neurology*. 39(Suppl. 2): 25-38, 1989.
36. Gormley, G.J., Stoner, E., Rittmaster, R.S., Gregg, H., Thompson, D.L., **Lasseter, K.C.**, Vlasses, P., and Stein E.: Effects of Finasteride, a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. *J. Clin. Endocrinol. Metabolism*. 70: 1136-1141, 1990.
37. Weinberger, M. H., Black, H. R., **Lasseter, K. C.**, Lewis, G.P., MacLeod, C. M., Pascual, A. V., Zager, P.G., DeSilva, J., Gourley, L.A., Bennett, D.A. and Whalen, J.J.: Diurnal Blood Pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril hydrochloride. *Clin. Pharmacol Ther*. 47: 608-617, 1990.
38. Waldmeier, F., Kaiser, G., Ackermann, R., Faigle, J.W., Wagner, J., Barner, A. and **Lasseter, K.C.**: The disposition of [¹⁴C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. *Xenobiotica*. 21: 251-261, 1991.
39. Moser, M., Abraham, P.A., Bennett, W.M., Brachfeld, N., Goodman, R.P., McKenney, J.M., Hollifield, J.W., Kirkendall, W.M., **Lasseter, K.C.**, Leon, A.S., Lunn, J., Miller, K., Morgenroth, J., Ruddy, M., Sambhi, M., Stein, W.J., Weber, M., Williams, R.L., Zawada, E., DeSilva, J., Gourley, L.A., and Whalen, J.J.: The effects of benzazepril, a new angiotensin-converting enzyme inhibitor in mild to moderate essential hypertension: A multicenter study. *Clinical Pharmacology and Therapeutics*. 49: 322-329, 1991.
40. Black, Henry R., Chrysant, S.G., Curry, C.L., Frishman, W.H., Grimm, R.H., **Lasseter, K.C.**, Okun, R., Pool, J.L., Raizada, V. and Vlachakis, N.D.: Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. *J. Clin. Pharmacol*. 32: 351-359, 1992.
41. Abraham, P.A., Halstenson, C.E., Macres, M., Opsahl, J., Rank, B., Scwenk, M., Lasky, L., Cohen, A., **Lasseter, K.C.**, Smith, D., Larkin, S. and Whalen, J.: Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies. *Clinical Pharmacology and Therapeutics*. 52: 205-213, 1992.

BIBLIOGRAPHY (Continued)

42. Frost, R.W., **Lasseter, K.C.**, Noe, A.J., Shamblen, E.C. and Lettieri, J.T.: Effects of aluminium hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. *Antimicrob. Agents Chemother.* 36: 830-832, 1992.
43. Kehe, C.R., **Lasseter, K.C.**, Miller, N.C., Wick, K., Shamblen, E.C., Ekholm, B.P., Sandahl, J., Chang, S., Goldlust, M.B., Kvam, D., and Harrison, L.I.: Comparative absorption of Atropine from a metered-dose inhaler and an intramuscular injection. *Therapeutic Drug Monitoring*, 14:132-134, 1992.
44. Laskin, O.L. Patterson, P., Shingo, S., **Lasseter, K.C.** and Shamblen, E.C.: Pharmacodynamics and Dose-Response Relationship of Famotidine: A Double Blind Randomized Placebo-Controlled trial. *J. Clinical Pharmacology.* 33: 636-639, 1993.
45. Schwartz, J., Laskin, O., Meeter, C.A., Patterson, P.M., Schneider, S., **Lasseter, K.C.** and Seibold, J.: Pharmacodynamics of MK-0963, a new 5-alpha-reductase inhibitor: Effects of serum androgen concentrations. *Clinical Pharmacology and Therapeutics*, 55:50-54, 1994.
46. Huang, S., Brusser, L., Chien, S., Simon, D., Smith, I., Abrams, L. and **Lasseter, K. C.:** Pharmacokinetics and Bioavailability of bemoradan, a long acting inodilator in healthy males. *Int. J. Clin. Pharmacol. Therapeutics* 32 (Suppl 2): 62-64, 1994.
47. Cheng, H., Schwartz, J., Lin, C., Amin, R., Seibold, J., **Lasseter, K.C.**, Ebel, D., Tocco, D., and Rogers, J.D.: The bioavailability and nonlinear pharmacokinetics of MK-679 in humans. *Biopharmaceutics and Drug Disposition.* 15: 409 - 418, 1994.
48. Ford, N.F., **Lasseter, K.C.**, VanHarken, D., Hammett, J., Raymond, R. and Manning, J.: Single-Dose and Steady-State Pharmacokinetics of Fosinopril and Fosinoprilat in Patients with Hepatic Impairment. *J. Clinical Pharmacology.* 35:145-150, 1995.
49. Gertz, B.J., Holland, S., Kline, W.F., Matuszewski, B.K., Freeman, A., Quan, H., **Lasseter, K.C.**, Mucklow, J.C., and Porras, A.G.: Studies of the oral bioavailability of alendronate. *Clinical Pharmacology and Therapeutics.* 58: 288-298, 1995.
50. Shah, A., Krol, G., Sunderasan, P., Lettieri, J., Falk, R., **Lasseter, K.** and Heller, A.: Pharmacokinetics of Nisoldipine coat-core formulation in subjects with liver cirrhosis. *American Journal Therapeutics.* 2:15-19, 1995.
51. **Lasseter, Kenneth C.**, Muller, F. Otto, Garrett, Bruce N., Marazzi, Phillip and Fodor, J.George: Pharmacokinetics, Pharmacodynamics and Clinical Utility of Nisoldipine Coat-core in the treatment of Essential Hypertension. *Cardiovascular Reviews and Reports.* 17: 28-37, 1996.

BIBLIOGRAPHY (Continued)

52. Schwartz, J., Van Hecken, A., deSchepper, P., Delepeleire, I., **Lasseter, K.C.**, Shamblen, E.C., Winchell, G., Constanzer, M., Chavez, C. Wang, D., Ebel, D., Justice, S. and Gertz, B.: Effect of MK-386, a novel inhibitor of Type (I) 5-alpha Reductase, alone and in combination with finasteride, on serum DHT (dihydrotestosterone) concentrations in Men. *J. Clin. Endocrinology and Metabolism*. 81: 2942-2947, 1996.
53. Thyrum, Per T., Yeh, C., Birmingham, B. and **Lasseter, K.C.**: The Pharmacokinetics of Meropenem in Subjects with Liver Disease. *Clin. Infect. Diseases*. 24(Suppl 2): S184-S190, 1997.
54. Fiddes, R., Blumenthal, T., Dawson, J., Dyckman, E., St.John Hammond, P., **Lasseter, K.C.**, Levine, B., Montoro, R., Niederman, A., Ratner, P., Rosenblatt, S., Toth, P., Vegnis, J. and Codispotti, J.: Evaluation of indapamide 1.25 mg once daily in elderly patients with mild-to-moderate hypertension. *Journal of Human Hypertension*. 11: 239-244, 1997.
55. Marino, M.R., Langenbacher, K., Ford, N.F., Beierle, F., Raymond, R.H., Shamblen, E.C. and **Lasseter, K.C.**: Effect of Hydrochlorthiazide on the Pharmacokinetics and Pharmacodynamics of the Angiotensin II blocker Irbesartan. *Clin. Drug Invest.* 14: 383-391, 1997.
56. Balani, S.K., Xu, X., Pratha, V., Koss, M., Amin, R., Dufresne, C., Miller, R., Arison, B., Doss, G., Chiba, M., Freeman, A., Holland, S., Schwartz, J., **Lasseter, K.C.**, Gertz, B., Isenberg, J., Rogers, J., Lin, J. and Baillie, T.: Metabolic Profiles of Montelukast Sodium (SingulairTM), a Potent Cysteinyl Leukotriene₁ Receptor Antagonist in Human Plasma and Bile. *Drug Metabolism and Disposition*, 25: 1282-1287, 1997.
57. Marino, M.T., Schuster, B.T., Brueckner, R.P., Lin, E., Kaminskis, A. and **Lasseter, K.C.**: Population Pharmacokinetics and Pharmacodynamics of Pyridostigmine Bromide for Prophylaxis against Nerve Agents in Humans. *J. Clin. Pharmacol.* 38: 227-235, 1998.
58. Marino, M. R., Langenbacher, K., Raymond, R., Ford, N. F. and **Lasseter, K.C.**: Pharmacokinetics and Pharmacodynamics of Irbesartan in Patients with Hepatic Cirrhosis. *J. Clin. Pharmacol.* 38: 347-356, 1998.
59. Brueckner, Ralf, **Lasseter, K.C.**, Lin, E.T. and Schuster, B.G.: First-Time-in-Man Safety and Pharmacokinetics of WR 238605, a new Antimalarial. *American J. Trop. Med. Hyg.* 58: 645-649, 1998.
60. Smith, D.A., Cleary, E., Watkins, S., Huffman, C., Dilzer, S. and **Lasseter, K.C.**: Pharmacokinetics and Pharmacodynamics of Zolmitriptan in Patients with Mild to Moderate Hypertension: A Double blind, placebo-controlled Study. *J. Clin. Pharmacol.* 38: 685-693, 1998.

BIBLIOGRAPHY (Continued)

61. Catella-Lawson, F., McAdam, B., Morrison, B., Kapoor, S., Kujubu, D., Antes, L., Tournier, B., Green, S., **Lasseter, Kenneth C.**, Quan, H., Gertz, B. and FitzGerald, G.A.: Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics and Vasoactive Eicosanoids. *J. Pharmacol. Exp. Ther.* 289: 735-741, 1999.
62. Bell, T.P., DeQuattro, V., **Lasseter, Kenneth C.**, Ruff, D., Hardison, J.D., Cushing, D., Kezer, A. and Michelson, E.L.: Effective Dose Range of Candesartan Cilexetil for Systemic Hypertension. *Amer. J. Cardiology* 83: 272-275, 1999.
63. Marino, M.R., Langenbacher, K., Ford, N.F., Raymond, R. H., Manning, J., Vesterqvist, O., Shamblen, E.C. and **Lasseter, K.C.**: Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients with Mild-to-Moderate Hypertension. *J. Cardiovasc Pharmacol Therapeut* 4: 67-75, 1999.
64. Everson, G., **Lasseter, K.C.**, Anderson, K., Bauer, L.A., Carithens, R., Wilner, K.D., Johnson, A., Anziano, R., Smolarek, T. and Turncliff, R.Z.: The Pharmacokinetics of Ziprasidone in Subjects with Normal and Impaired Hepatic Function. *Br. J. Clin. Pharmacol.* 49 (Suppl 1): 21-26, 2000.
65. Swan, S.K., Rudy, D.W., **Lasseter, Kenneth C.**, Ryan, C.F., Buechel, K.L., Lambrect, L.J., Pinto, M.B., Dilzer, S.C., Obrda, O., Sundblad, K.J., Gumbs, C.P., Ebel, D.L., Quan, H., Larson, P.J., Schwartz, J.I., Musliner, T.A., Gertz, B.J., Brater, C. and Yao, Siu-Long. Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons receiving a Low-Salt Diet. *Annals of Internal Medicine*, 133: 1-9, 2000.
66. Choudbury, S., Hirschberg, Y., Filipek, R., **Lasseter, Kenneth C.** and McLeod, J.: Single-Dose Pharmacokinetics of Nateglinide in Subjects with Hepatic Cirrhosis. *J. Clinical Pharmacol.* 40: 634-640, 2000.
67. Mazzu, Arthur L., **Lasseter, Kenneth C.**, Shamblen, E. Cooper, Agarwal, Vipin, Lettieri, John T. and Sundaresen, Pavur: Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. *Clin Pharmacol Ther.* 68: 391-400, 2000.
68. Prueksaritanont, T., Vega, J., Zhao, J., Gagliano, K., Kuznetsova, O., Musser, B., Amin, R., Lui, L., Roadcap, B.A., Dilzer, S., **Lasseter, K.C.** and Rogers, J.D.: Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects. *J. Clin. Pharmacol.* 41: 573-581, 2001.
69. Zhou, H., Khalilieh, S., Svendsen, K., Pommier, F., Osborne, S., Appel-Dingemans, S., **Lasseter, Kenneth C.** and McLeod, J.F.: Tegaserod Coadministration does not alter the Pharmacokinetics of Theophylline in Healthy Subjects. *J. Clin. Pharmacol.* 41: 987-993, 2001.
70. Kovarik, John M., Sabia, H.D., Figueiredo, J., Zimmermann, H., Dilzer, S., **Lasseter, Kenneth C.** and Rordorf, C.: Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. *Clinical Pharmacology and Therapeutics.* 70: 425-430, 2001.

BIBLIOGRAPHY (Continued)

71. Abrams, L.S., Skee, D.M., Natarajan, J., Wong, F.A. and **Lasseter, K.C.**: Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants. *Contraception*. 64: 287-294, 2001.
72. Campese, V.M., **Lasseter, Kenneth C.**, Ferrario, C. M., Smith, W.B., Ruddy, M.C., Grim, C. E., Smith, R. D., Vargas, R., Habashy, M.F., Vesterqvist, O., Delaney, C. L. and Liao, W.: Omapatrilat versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients. *Hypertension*. 38: 1342-1348, 2001.
73. Halpin, R.A., Porras, A.G., Geer, L.A., Davis, M.R., Cui, D., Doss, G.A., Woolf, E., Musson, D., Matthews, C., Mazenko, R., Schwartz, J., **Lasseter, K.C.**, Vyas, K.P. and Baillie, T.A.: The Disposition and Metabolism of Rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. *Drug Metabolism and Disposition*, 30: 684-693, 2002.
74. Schwartz, J.I., Vandormael, K., Malice, M.P., Kalyani, R., **Lasseter, K.C.**, Holmes, G.B., Gertz, B.J., Gottesdiener, K., Laurenzi, M., Redfern, K-J. and Brune, K.: Comparison of Rofecoxib, Celecoxib and Naproxen on Renal Function in Elderly Subjects Receiving a Normal-Salt Diet. *Clinical Pharmacology and Therapeutics*, 72:50-61, 2002.
75. Guzzo, C.A., Furtek, C.L., Porras, A., Chen, C., Tipping, R., Clineschmidt, C., Sciberras, D.G., Hsieh, Y-K. and **Lasseter, K.C.**: Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of Ivermectin in Healthy Adult Subjects. *J. Clinical Pharmacology* 42: 1122-1133, 2002.
76. Huang, F., **Lasseter, Kenneth C.**, Janssens, L., Verhaeghe, T., Lau, H. and Shao, Q.: The assessment of the potential pharmacokinetic interaction of galantamine and resperidone. *J. Clinical Pharmacology* 42: 1341-1351, 2002.
77. Rodrigues, A.D., Halpin, R. A., Geer, L.A., Cui, D., Woolf, E. J., Matthews, C., Gottesdiener, K. M. Larson, P.J., **Lasseter, Kenneth C.**, and Agrawal, N.G.B.: Absorption, Metabolism, And Excretion Of Etoricoxib, A Potent And Selective Cyclooxygenase-2 Inhibitor, in Healthy Male Volunteers. *Drug Metabolism and Disposition*. 31: 224-232, 2003.
78. Agrawal, N.G.B., Porras, A.G., Matthews, C.Z., Rose, M.J., Woolf, E.J., Musser, B.J., Dynder, A.L., Mazina, K., **Lasseter, Kenneth C.**, Hunt, T.L., Schwartz, J.I., McCrea, J.B. and Gottesdiener, K.M.: Single- and Multiple-Dose Pharmacokinetics of Etoricoxib, a Selective Inhibitor of Cyclooxygenase-2 in Man. *J. Clin. Pharmacology*. 43: 268-276, 2003.
79. Simonson, S.G., Martin, P.D., Mitchell, P., Schneck, D.W., Warwick, M.J. and **Lasseter, Kenneth C.**: Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. *European J. Clinical Pharmacology*, 58: 669-675, 2003.

BIBLIOGRAPHY (Continued)

80. Van Schaik, E.A., Lechat, P., Remmerie, B., Ko, G., **Lasseter, K.C.** and Mannaert, E.: Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. *Clinical Therapeutics* 25: 1687-1699, 2003.
81. Agrawal, Nancy G. B., Rose, Mark J., Matthews, Catherine Z., Woolf, Eric J., Porras, Arturo G., Geer, Leslie A., Larson, Patrick J., Cote, Josee, **Lasseter, Kenneth C.**, Dilzer, Stacy C., Alam, Imtiaz, Petty, Kevin J., Gottesdiener Keith M.: Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment. *J. Clin Pharmacol.* 43: 1136-1148, 2003.
82. Schwartz, J.I., Larson, P.J., Porras, A.G., Viswanathan-Aiyer, K.J., Agrawal, N.G.B., **Lasseter, K. C.**, Mazenko, R.S., Merschman, S.A. and Gertz, B.J. Pharmacokinetic Evaluation of Rofecoxib: Comparison of Tablet and Suspension Formulations. *Clinical Drug Investigations*, 23: 503-509, 2003.
83. **Lasseter, Kenneth C.**, Dilzer, S.C., Vargas, R., Noveck, R. and Waldman, S.: A Phase I open-label study to investigate the pharmacokinetics and safety of Ebastine in patients with impaired hepatic function compared with healthy volunteers. *Clin Pharmacokinet.* 43: 121-129, 2004.
84. Stone, J.A., Xin, X., Winchell, G.A., Deutsch, P. J., Pearson, P.G., Migoya, E. M., Mistry, G. C., Xi, L., Miller, A., Sandhu, P., Singh, R., deLuna, F., Dilzer, S.D. and **Lasseter, K.C.**: Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma. *Antimicrobial Agents and Chemotherapy.* 48: 815-823, 2004.
85. Schneck, D.W., Birmingham, B.K., Zalikowski, J.A., Mitchell, P.D., Wang, Y., Martin, P.D., **Lasseter, Kenneth C.**, Brown, C.D.A., Windass, Amy and Raza. Ali: The Effect of Gemfibrozil on the Pharmacokinetics of Rosuvastatin. *Clinical Pharmacology and Therapeutics.* 75: 455-463, 2004.
86. Arthur J Bergman PhD, Gail Murphy MD, Joanne Burke BS, Jamie Zhao PhD, Robert Valesky MS, Lida Liu MS, **Kenneth C. Lasseter MD**, Weili He PhD, Thomayant Prueksaritanont PhD, Yue Qiu MS, Alan Hartford PhD, Jose M. Vega, John F. Paolini MD PhD: Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. *J. Clinical Pharmacology*, 44: 1054-1062, 2004.
87. Kalbag, J., Yeh, C.M., Milosavljev, S., **Lasseter, Kenneth C.**, Oberstein, S. and Rordorf, C.: No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. *Pharmacological Research*, 50: 181-186, 2004.
88. Stone, J. A., Migoya, E.M., Hickey, L., Winchell, G.A., Deutsch, P. J., Ghosh, K., Freeman, A., Bi, S., Desai, R., Dilzer, S.C., **Lasseter, Kenneth C.**, Kraft, W.K., Greenberg, H. and Waldman, S.: Potential for Interactions between Caspofungin and Nelfinavir or Rifampin. *Antimicrobial Agents and Chemotherapy.* 48 (11): 4306-4314, 2004.

BIBLIOGRAPHY (Continued)

89. **Lasseter, Kenneth C.**, Porras, A.G., Denker, A., Santhanagopal, Anu and Daifotis, A.: Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. *Clin. Drug Invest.* : 25: 107-114, 2005.
90. Kovarik JM, Schmouder RL, Serra D, Wang Y, Wiegand H., Dilzer S and **Lasseter Kenneth C.**: FTY720 pharmacokinetics in mild to moderate hepatic impairment. *J. Clin Pharmacol.* 45: 446-452, 2005.
91. Simonson, SG, Martin, PD, Mitchell, PD, **Lasseter, KC**, Gibson, G and Schneck, DW: Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. *J Clin Pharmacol.*: 45: 927-934, 2005.
92. Turncliff, RZ, Dunbar, JL, Dong, Q, Silverman, BL, Ehrich, EW, Dilzer, SC and **Lasseter, Kenneth C**: Pharmacokinetics of Long-acting Naltrexone in Subjects with Mild to Moderate Hepatic Impairment. *J. Clin. Pharmacol.* 45: 1250-1267, 2005.
93. Zimmerman, J.J., **Lasseter, Kenneth C.**, Lim, H-K, Harper, D., Dilzer, S.C. and Parker, V.: Pharmacokinetics of sirolimus (Rapamycin), an immunosuppressive agent, in subjects with mild to moderate hepatic impairment. *J. Clin. Pharmacol.*, 45: 1368-1372, 2005.
94. Migoya, EM, Bergman, A., Hreniuk, D., Matthews, N., Yi, B., Roadcap, B., Valesky, R., Liu, L., Riffel, K., Groff, M., Zhao, J.J., Musson, D.G., Gambale, J., Kosoglou, T., Statkevich, P., **Lasseter, Kenneth C.**, Laurent, A., Johnson-Levonas, A, Murphy, G., Gottesdiener, K. and Paolini, J.: Bioequivalence of the ezetimibe/simvastatin combination tablet and co-administration of ezetimibe and simvastatin as separate tablets in healthy subjects. *International Journal of Clinical Pharmacology and Therapeutics.* 44: 83-92, 2006.
95. Dunbar, JL, Turncliff, RZ, Dong, Q, Silverman, BL, Ehrich, EW and **Lasseter, Kenneth C**: Single and Multiple Dose Pharmacokinetics of Long-acting Injectable Naltrexone. *Alcohol Clin Exp Res.*, 30: 480-90, 2006.
96. Polsky-Fisher, S.L., Vickers, S., Cui, D., Sabramian, R., Arison, B., Agrawal, N.G.B., Goel, T.V., Vessey, L.K., Murphy, M.G., **Lasseter, K.C.**, Simpson, R., Vega, J.M. and Rodrigues. D.: Metabolism and Disposition of a Potent and Selective GABA-A_{α2/3} Receptor Agonist in Healthy Male Volunteers. *Drug Metab Dispos.* 34: 1004-1011, 2006.
97. Kochansky, C.J., Rippley, R.K., Yan, K.X., Song, H., Wallace, M.A., Dean, D., Jones, A.N., **Lasseter, Kenneth**, Schwartz, J., Vincent, S.H., Franklin, R.B. and Wagner, J.: Absorption, Metabolism and Excretion of [¹⁴C]MK-0767 in Humans. *Drug Metab Dispos.* 34: 1457-1461, 2006.
98. Sandage, B.W., Sabounjian, L., Shipley, J., Profy, A., **Lasseter, Kenneth C.**, Fox, L. and Harnett, M.: Predictive Power of an *In Vitro* System to Assess Drug Interactions of an Antimuscarinic Medication: A Comparison of *In Vitro* and *In Vivo* Drug-Drug Interaction Studies of Trosipium Chloride with Digoxin. *J. Clin. Pharmacol.* 46: 776-784, 2006.

BIBLIOGRAPHY (Continued)

99. Herman, G.A., Bergman, A., Liu, F., Stevens, C., Wang, A.Q., Zeng, W., Chen, L., Snyder, K., Hilliard, D., Tanen, M., Tanaka, W., Meehan, A.G., **Lasseter, Kenneth**, Dilzer, S., Blum, R. and Wagner, J.A.: Pharmacokinetics and pharmacodynamic effects of the Oral DPP-IV inhibitor Sitagliptin, in middle-aged obese subjects. *J Clin Pharmacol.* 46: 876-886, 2006.
100. Herman, G.A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., **Lasseter, K. C.**, Kipnis, M.S., Snyder, K., Hilliard, D., Tanen, M., Cilissen, C., De Smet, M., deLepelre, I., Van Dyck, K., Wang, A.Q., Zeng, W., Davies, M.J., Tanaka, W., Holst, J., Deacon, C., Gottesdiener, K. and Wagner, J.: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. *J. Clin. Endocrinol. Metab.* 91: 4612-4619, 2006.
101. Krishna, R., Bergman, A., Larson, P., Cote, J., **Lasseter, K.C.**, Dilzer, S., Wang, A., Zeng, W., Chen, L., Wagner, J. and Herman, G.: Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects. *J. Clin Pharmacol.* 47: 165-174, 2007.
102. Vincent, S.H., Reed, J.R., Bergman, A.J., Elmore, C.S., Zhu, B., Xu, S.S., Ebel, D., Larson, P.J., Zeng, W., Chen, L., Dilzer, S.C., **Lasseter, K.C.**, Gottesdiener, K.M., Wagner, J.A. and Herman, G.A.: Metabolism and Excretion of the DPP-4 inhibitor [¹⁴C]sitagliptin in humans. *Drug Metab Dispos.* (E-published ahead of print 12 Jan 2007.) 35: 533-538, 2007.
103. He, Y.L., Sabo, R., Campestrini, J., Wang, Y., Ligueros-Saylan, M., **Lasseter, K.C.**, Dilzer, S.C., Dole, W. P., Howard, and D.: The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin, *European J. Clin. Pharmacol.*, (E-published ahead of print 8 May 2007) 63: 677-686, 2007.
104. **Lasseter, Kenneth C.**, Dilzer, S.C. and Smith, N.: Effect of Intravenous Conivaptan on the QTc Interval and other Electrocardiographic Parameters in Healthy Volunteers. *Advances in Therapy*, 24: 310-318, 2007.
105. Bergman, A., Mistry, G., Luo, W.L., Liu, O., Stone, J., Wang, A., Zeng, W., Chen, L., Dilzer, S., **Lasseter, K.C.**, Herman, G.A., Wagner, J.A. and Krishna, R.: Dose-proportionality of a final market image sitagliptin formulation, an oral depeptidyl peptidase-4 inhibitor, in healthy volunteers. *Biopharm Drug Dispos.* 28: 307-313, 2007.
106. Bergman, A., Ebel, D., Liu, F., Stone, J., Wang, A., Zeng, W., Chen, L., Dilzer, S. C., **Lasseter, K. C.**, Herman, G., Wagner, J. and Krishna, R.: Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. *Biopharm Drug Dispos.* 28: 315-322, 2007.

BIBLIOGRAPHY (Continued)

107. **Lasseter, Kenneth C.**, Gambale, J., Jin, B. Bergman, A., Constanzer, M., Dru, J. Han, T., Majumdar, A., Evans, J. and Murphy, M.G.: Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects. *J. Clin. Pharmacol.* (E-published ahead of print 24 May 2007) 47: 834-840, 2007.
108. Kassahun, K., McIntosh, I., Hreniuk, D., Merschman, S., **Lasseter, K.C.**, Azrolan, N., Iwamoto, M. Wagner, J. A and Wenning L. A.: Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the HIV-1 Integrase Enzyme. *Drug Disposition and Metabolism* (E-published ahead of print 25 June 2007) 35: 1657-1663, 2007.
109. Mistry, G.C., Migoya, E., Stone, J., Winchell, G., Hesney, M., Bi, S., Dilzer, S., **Lasseter, K.C.** and Deutsch, P.: Single And Multiple-Dose Administration Of Caspofungin In Patients With Hepatic Insufficiency: Implications For Safety And Dosing Recommendations. *J. Clin. Pharmacol.*, 47: 951-961, 2007.
110. Schwartz, J.I., Thach, C., **Lasseter, Kenneth C.**, Miller, J., Hreniuk, D., Hilliard, D., Snyder, K.M., Gertz, B. J. and Gottesdiener, K.M.: Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure and other renal function indicators in elderly subjects consuming a controlled sodium diet. *J. Clin. Pharmacol.* 47: 1521-1531, 2007.
111. Iwamoto, M., Wenning, L.A., Petry, A., Laethem, M., De Smet, M., Kost, J. T., Merschman, S., Stohmaier, K., Ramael, S., **Lasseter, K.C.**, Stone, J.C., Gottesdiener, K.M., Wagner, J. A.: Safety, Tolerability and Pharmacokinetics of Raltegravir after Single and Multiple Doses in Healthy Subjects. *Clin Pharmacol. Therap.*, 83: 293-298, 2008.
112. **Lasseter, Kenneth C.**, Shaughnessy, L., Cummings, D., Pezzullo, J.C., Wargin, W., Gagnon, R., Oliva, J. and Kosutic, G.: Ghrelin Agonist (TZP-101): Safety, Pharmacokinetics and Pharmacodynamic Evaluation in Healthy Volunteers: A Phase I, First in Human Study. *J Clin. Pharmacol.* 48:193-202, 2008.
113. Mistry, G.C., Maes, A.L., **Lasseter, Kenneth C.**, Davies, M.J., Gottesdiener, K., Wagner, J.A. and Herman, G.A.: Effect of Sitagliptin, A Dipeptidyl Peptidase-4 Inhibitor on Blood Pressure in Non-Diabetic Patients With Mild To Moderate Hypertension. *J Clin Pharmacol.* (E-published ahead of print 19 March 2008 doi: 10.1177/0091270008316885) 48: 592-598, 2008.
114. Wenning, L.A., Friedman, E., Kost, J., Breidinger, S., Stek, J., **Lasseter, K.C.**, Gottesdiener, K. M., Chen, J., Wagner, J.A., Stone, J.A. and Iwamoto, M.: Lack of Significant Drug Interaction between raltegravir and tenofovir. *Antimicrobial Agents and Chemotherapy* (E-published ahead of print July 14, 2008) 52: 3253-3258, 2008

BIBLIOGRAPHY (Continued)

115. Schwartz, J.I., Dunbar, S., Yuan, J., Li, S., Gipson, A., Rosko, K., Johnson-Levonas, A., **Lasseter, Kenneth C.** and Wagner, J.: Influence of Taranabant, an Orally-Active, Highly-Selective, Potent, Cannabinoid-1 Receptor (CB-1R) Inverse Agonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin. *Advances in Therapy*. 25(11):1175-90, 2008.
116. Schwartz, J.I., Dunbar, S., Yuan, J., Li, S., Miller, D.L., Rosko, K., Johnson-Levonas, A., **Lasseter, Kenneth C.** and Wagner J.A.: Influence of Taranabant, A Novel Selective Cannabinoid-1 Receptor (CB-1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Plasma Pharmacokinetics. *J Clin Pharmacol*. 49: 72-79, 2009 (E-published ahead of print Oct 20, 2008).
117. Kovarik, J.M., Dole, K., Riviere, G., Pommier, F., Maton, S., Jin, Y., **Lasseter, Kenneth C.**, Schmouder, R. L.: Ketoconazole increases fingolimod blood levels in a drug interaction via CYP_{4F2} inhibition. *J Clin Pharmacol*. 49: 212-218, 2009 (E-published ahead of print December 31, 2008).
118. Migoya, E., Stevens, C., Bergman, A.J., Luo, W.L., **Lasseter, Kenneth C.**, Dilzer, S., Davies, M.J., Wagner, J.A. and Herman, G.A.: Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. *Can J. Clin Pharmacol* 16(1): e165-e170, 2009. (E- published ahead of Print 16 Feb 2009).
119. Iwamoto, M., Hanley, W.D., Petry, A.S., Friedman, E.J., Kost, J.T., Breidinger, S.A., **Lasseter, K. C.**, Robson, R., Lunde, N.M., Wenning, L.A., Stone, J.A., Wagner, J.A.: Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics. *Antimicrob. Agents Chemother.* ; 53(5): 1747-1752, 2009. (E published ahead of print 17 Feb 2009 doi:10.1128/AAC.01194-08).
120. Schwartz, Jules I., Liu, Fang, Stroh, M., Gipson, Adrianna, Johnson-Levonas, Amy O., **Lasseter, Kenneth C.**, Lai, Eseng, Wagner, John A.: Influence of Laropiprant, a Selective Prostaglandin D₂ Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin. *Amer. J. Therapeutics*, 16: 215-223, 2009
121. Bergman, A.J., Stevens, C., Bingming, Y., Luo, W., Chen, L., Zeng, W., Wang, A., Winchell, G., Snyder, K., Flynn, M., Tanaka, W., **Lasseter, Kenneth C.**, Dilzer, S., Langdon, R., Gottesdiener, K., Wagner, J. and Herman, G.: Pharmacokinetic and Pharmacodynamic Parameters of Sitagliptin Compared across Normal Subjects Differing in Age, Sex, and Level of Obesity. *J Clin Pharmacol*. *In Press*.
122. Haffey, Mary B., Buckwalter, Mary, Zhang, Pinggao, Homolka, Robert, Martin, Patrick, **Lasseter, Kenneth C.**, Ermer, James C.: Effects of Omeprazole on the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Extended-Release Mixed Amphetamine Salts in Adults. *Postgraduate Medicine, In Press*.

BIBLIOGRAPHY (Continued)

123. **Lasseter, Kenneth C.**, Aubets, Jordi, Chuecos, Ferran and Garcia Gil, Esther: Aclidinium Bromide, a Long-Acting Anticholinergic, Does Not Affect QT Interval in Healthy Subjects. *J. Clinical Pharmacol.* Submitted for Publication.
124. Erichsen, L., Klitgaard, T., **Lasseter, Kenneth C.**, An, B. and Bright, G.: Development of an Indirect Stimulus-Response Pharmacodynamic Model for Growth Hormone and IGF-1 in Adults following Single-dose Growth Hormone Treatment. *Hormone Research.* Submitted for Publication.
125. Migoya, Elizabeth, Larson, Patrick, Bergman, Arthur, Miller, Jutta, Johnson-Levonas, Amy O., **Lasseter, Kenneth C.** and Wagner, John A.: Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Estradiol and Norethindrone Plasma Pharmacokinetics in Healthy Female Subjects. *J Clin Pharmacol.* Submitted for Publication.
126. Krishna, Rajesh, Garg, A., Panebianco, D., Cote, J., Bergman, A.J., vanHoydonck, P., Laethem, T., vanDyck, K., Chen, J., Chavez-Eng, C., Archer, L., Lutz, R., Hilliard, D., Snyder, K., Jin, B., vanBortel, L., **Lasseter, K.C.**, Gottesdiener, K., Wagner, J.: Single-Dose Pharmacokinetics and Pharmacodynamics of Anacetrapib, a potent Cholesteryl Ester Transfer Protein (CETP) inhibitor, in healthy Subjects. *J. Clin Pharmacol.* Submitted for Publication.
127. Wang, Y.H., Liu, F., Luk, J.A.M., Nirula, A., Johnson-Levonas, A.O., **Lasseter, Kenneth C.**, Marbury, T. C., Lunde, N.M., Wagner, J. and Lai, Eseng: Pharmacokinetics of Laropiprant, a selective Prostaglandin D₂ Receptor 1 Antagonist in Subjects with Moderate Hepatic Impairment. *J. Clinical Pharmacol.* Submitted for Publication.

ABSTRACTS

Kenneth C. Lasseter, M.D.

1. **Lasseter, K.C.**, Palmer, R.F., Levey, G.S. and McCarthy, J.S.: Sulfonylurea drugs: New Inotropic Entities. Clin. Res. 20: 69, 1972. (Presented at Southern Society for Clinical Investigation meeting, New Orleans, Louisiana, January, 1972).
2. Hildner, F.J., Ramaswamy, K., Javier, R.P., **Lasseter, K.C.**, Samet, P. and Yeh, B.K.: Hemodynamic effects of tolbutamide in man. Circulation 44, Suppl. 11: 178, 1971.
3. deGuzman, N.T., Pressman, B.C., **Lasseter, K.C.**, and Palmer, R.F.: X537A, A new cardiac inotropic agent. Clin. Res. 21: 413, 1973.
4. **Lasseter, K.C.**, Meier, C., Abelleira, J. and Pressman, B.C.: Effects of a calcium ionophore on cardiac excitation and contraction. Circulation 48, Suppl. IV: 131, 1973. (Presented at 46th Annual Scientific Sessions of American Heart Association, Atlantic City, New Jersey, November 1973).
5. Zoble, R.G., and **Lasseter, K.C.**: Electrophysiologic action of a new antiarrhythmic agent, aprindine. Clin. Res. 22: 325A, 1974.
6. Palmer, R.F., van Breemen, C. and **Lasseter, K.C.**: Lanthanum as a means of identifying loci of cardiac drug action. Fed. Proc. 33: 517, 1974.
7. Zoble, R. May, L. and **Lasseter, K.C.**: Conduction velocity at varying cycle lengths under the influence of aprindine and its quaternary derivative. Fed. Proc. 35: 320, 1976. (Presented at 60th Annual FASEB Meeting, April 11-16, 1976, Anaheim, California.)
8. Gray, C.G. and **Lasseter, K.C.**: A six-compartment analog model simulation of digoxin pharmacokinetics in normal and pathologic states. Clin. Res. 24: 508A, 1976. (Presented at 5th Annual Meeting of American College of Clinical Pharmacology, April, 30, 1976, Philadelphia, PA.)
9. Palmer, R.F. and **Lasseter, K.C.**: Nitroprusside and Aortic Dissecting Aneurysm, New England J. Med. 294: 1403-1404, 1976.
10. Meier, C.F., Jr., **Lasseter, K.C.** and Pressman, B.C.: Alteration of intracellular sodium activity in canine cardiac Purkinje fibers by the ionophore Monensin. Pharmacologist, 18: 122, 1976. (Presented at 1976 Fall Meeting of the American Society for Pharmacology and Experimental Therapeutics, New Orleans, Louisiana, August 15-19, 1976.)

ABSTRACTS (Continued)

11. Abelleira, J. and **Lasseter, K.C.**: Pharmacologic investigation of the mechanisms for rest period potentiation of contractile force in cardiac muscle. *Pharmacologist*, 18: 122, 1976. (Presented at 1976 Fall Meeting of the American Society for Pharmacology and Experimental Therapeutics, New Orleans, Louisiana, August 15-19, 1976.)
12. Zoble, R.G. and **Lasseter, K.C.**: Pharmacologic modification of parameters reflecting sodium currents. *Pharmacologist* 19: 151, 1977. (Presented at 1977 Fall Meeting of ASPET, Columbus, Ohio, August 21-25, 1977.)
13. Zoble, R.G. and **Lasseter, K.C.**: Interrelation of membrane potential upstroke velocity and action potential overshoot. *Fed. Proc.* 37: 789, 1978. (Presented at 1978 Spring FASEB Meeting, Atlantic City, NJ, April 9-14, 1978.)
14. Hayes, S.L., **Lasseter, K.C.** and Palmer, R.F.: Prazosin: Plasma levels and effect in normal humans. *Clinical Pharmacology and Therapeutics* 25: 228, 1979. (Presented at 1979 Annual Meeting ASCPT, Kansas City, MO, 21-23, 1979.)
15. Hayes, S.L., **Lasseter, K.C.**, Davalos, D. and Palmer, R.F.: Amrinone, A novel cardiac inotrope: Effects after oral administration in normal man. *Clin. Res.*, 27: 542A, 1979.
16. Weidler, D.J., Garg, D.C., **Lasseter, K.C.** and Jallad, N.S.: The effect of chronic propranolol administration on the pharmacokinetics of lidocaine in humans. (Presented at World Conference on Clinical Pharmacology and Therapeutics, London, August 3-9, 1980.)
17. **Lasseter, K.C.**, Jallad, N.S., Weidler, D.J. and Garg, D.C.: The effect of propranolol administration on the pharmacokinetics of procainamide. (Accepted for presentation to 1980 Spring ASPET Anaheim, Calif., April 14-18, 1980.) *Federation Proc.* 39: 746, 1980.
18. Garg, D.C., Jallad, N.S., **Lasseter, K.C.** and Weidler, D.J.: Pharmacokinetic interactions of alcohol and acetaldehyde with propranolol. (Presented at 9th Annual Meeting American College of Clinical Pharmacology, Washington, D.C., May 8-9, 1980.) *Clin. Res.* 28: 589A, 1980.
19. Weidler, D.J., Garg, D.C., **Lasseter, K.C.** and Jallad, N.: Disposition Kinetics of Lidocaine during chronic administration of propranolol. (Presented at 9th Annual Meeting American College of Clinical Pharmacology, Washington, D.C., May 8-9, 1980). *Clin. Res.* 28: 591A, 1980.
20. **Lasseter, K.C.**, Garg, D.C., Hayes, S.L., Palmer, R.F., and Kullberg, P.: Pharmacokinetics of amrinone following oral administration to normal human subjects. (Presented at 9th Annual Meeting American College of Clinical Pharmacology, Washington, D.C., May 8-9, 1980.) *Clin. Res.* 28: 589A, 1980.

ABSTRACTS (Continued)

21. Keenan, R.E., **Lasseter, K.C.**, Brinkerhoff, J.H. and Morely, E.M.: Reversal of Hypotensive Effect of high dose Bethanidine with Tricyclic Protriptyline. (Presented at 76th Annual Scientific Assembly of the Southern Medical Association, Atlanta, Georgia, October 30-November 2, 1982). J. South. Med. Assn., 98: 612, 1982.
22. **Lasseter, K.C.**, Shamblen, E., Woodward, D. and Stokstadt, E.: Bioavailability of oral and parenteral formulations of Leucovorin. (Presented at 84th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, San Diego, California, March 9-11, 1983). Clinical Pharmacology Therapeutics, 33: 222, 1983.
23. **Lasseter, K.C.**, Barkin, J., Shamblen, E.C. and Murdoch, A.A.: Upper Gastrointestinal injury associated with wax matrix but not micro-encapsulated potassium chloride (KC1) and Anticholinergic Therapy, (Presented at 84th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, San Diego, California, March 9-11, 1983). Clinical Pharmacology Therapeutics, 33: 217, 1983.
24. Locniskar, A., **Lasseter, K.C.**, Freeland, G.R. and Greenblatt, D.J.: Pharmacokinetics and Bioavailability of Ciramadol, a new Analgesic. (Presented at 12th Annual Meeting of American College of Clinical Pharmacology, Washington, D.C., April 28-29, 1983.) Clin. Research 36: 914, 1983.
25. Barkin, J.S., Harary, A.M., Shamblen, E.C. and **Lasseter, K.C.**: Potassium Chloride and Gastrointestinal Injury. Annals of Internal Medicine, 98: 262, 1983.
26. **Lasseter, K.C.**, Shamblen, E.C., Lowenthal, D. and Saris, S.D.: Steady State Pharmacokinetics of nitrendipine in Hepatic Insufficiency. (Presented at International Nitrendipine Symposium, Interlaken, Switzerland. April 12-14, 1984). J. Cardiovasc. Pharmacology, 6: S977, 1984.
27. Given, B.D., Vita, N.A., Black, H., Francis, C., **Lasseter, K.C.**, Mickiewicz, C., Akestor, J., Koury, K. and Dzau, V.: Chronic Prostaglandin E Analog Elicits Renal and Hormonal Compensatory Mechanisms in Human Hypertension. Circulation, 70, Suppl. II: 63, 1984. (Presented at American Heart Association 57th Scientific Sessions, Miami Beach, Florida, November 12-15, 1984).
28. **Lasseter, K.C.**, Shamblen, E.C., Smallridge, R.C., Verna, P.S., Goldlust, M.B., Harrison, L.I., Chang, S.F., Gam, V.W. and Kvam, D.C.: Comparative Absorption of Inhaled and Intramuscular (IM) Atropine Sulfate (AS). Clin. Pharmacology Therapeutics, 37: 207, 1985. (Presented at 86th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, San Antonio, Texas, March 28-30, 1985).
29. **Lasseter, K.C.**, Chiang, S.T., Rogers, S.L. and Walker, B.R.: Pharmacokinetics of Oxaprozin in Patients with Hepatic Impairment. Clinical Research, 33: 284A, 1985.

ABSTRACTS (Continued)

30. McQuinn, R., Weeks, C., Kvam, D., Fredell, P., Carlson, G., Miller A., **Lasseter, K.C.** and Shamblen, E.C.: Pharmacokinetics of Flecainide in Elderly Subjects. (Presented at 87th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Washington, D.C., March 19-22, 1986.). *Clin. Pharmacology Therapeutics* 39: 210, 1986.
31. Harris, B.J., **Lasseter, K.C.**, Woodward, D.L. and Koralek, A.V.: The assessment of cutaneous blood flow using a laser Doppler perfusion monitor following repeated administration of Viprostol, a topically active synthetic prostaglandin. (Presented at 6th International Conference on Prostaglandins and Related Compounds, Lisbon, Portugal. May 7-21, 1986).
32. **Lasseter, K.C.**, Shamblen, E.C., Lettieri, J., Kroll, G., Taylor, R.J. and Fein, S.H.: Dose Proportional Pharmacokinetics of Nisoldipine in Healthy Volunteers. (Presented at 88th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Orlando, Florida, March 18-21, 1987). *Clinical Pharmacology and Therapeutics*, 41: 234, 1987.
33. Murdoch, A.A., Shamblen, E.C., **Lasseter, K.C.**, Rubin, A., Knadler, M.P., Bergstrom, R.F. and Callaghan, J.T.: Nizatidine Pharmacokinetics in Hepatic Disease. Presented at 11th Annual Meeting of Associates of Clinical Pharmacology, May 1987). *J. Clin. Res. and Drug Dev.* 1: 91-93, 1987.
34. Lettieri, J., Frost, R.W., Krol, G. **Lasseter, K.C.** and Shamblen, E.C.: Effects of Cirrhosis on Ciprofloxacin Pharmacokinetics. (Presented at 27th Interscience Conference on Antimicrobial agents and Chemotherapy, October 4-7, 1987, New York, N.Y.). *J. Antib. and Antimicrob Chemotherapy* 33:318, 1987.
35. Harrison, L., Chang, S., Miller, N., Kvam, D., Kehe, C., Riedel, D., Wicks, K., Sandahl, J., **Lasseter, K.C.**, Shamblen, E.C.: Absorption of Aerosolized Atropine Sulfate. (Presented at 89th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, San Diego, California, March 9-11, 1988). *Clinical Pharmacology and Therapeutics* 43: 148, 1988.
36. **Lasseter, K.C.**, Shamblen, E.C., Murdoch, A.A., Marino, M., Minor, M., and Kraml, M.J.: Pharmacokinetics of Etodolac in patients with Hepatic Cirrhosis. (Presented at 17th Annual Meeting of the American College of Clinical Pharmacology, Orlando, FL, October 31 - November 3, 1988). *J. Clinical Pharmacology*, 28: 933, 1988.
37. **Lasseter, K.C.**, Shamblen, E.C., Krol, G.T., Frost, R.W. and Lettieri, J.T.: Pharmacokinetics of Nimodipine and its metabolites at four different doses. (Presented at the 17th Annual Meeting of the American College of Clinical Pharmacology, Orlando, FL, October 31 - November 3, 1988). *J. Clinical Pharmacology*, 28: 917, 1988.

ABSTRACTS (Continued)

38. Frost, R.W., Noe, A., Shamblen, E.C., and **Lasseter, K.C.**: Effect of Aluminum Hydroxide and Calcium Carbonate, Antacids on ciprofloxacin bioavailability. (Presented at 90th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Nashville, Tenn., March 1989). *Clinical Pharmacology and Therapeutics*, 45: 165, 1989.
39. Gormley, G., Rittmaster, R.S., Gregg, H., **Lasseter, K.C.**, Ferguson, D., and Stoner, E.: Dose response effect of an orally active 5-alpha-reductase inhibitor in man. (Presented at the annual meeting of The Endocrine Society, 1989). *J. Endocrinology*.
40. Laskin, O.L., Patterson, P., Shingo, S., **Lasseter, K.C.**, Shamblen, E. and Murdoch, A.A.: Famotidine dose - pH relationship. (Presented at 91st Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, San Francisco, California, March 21-23, 1990). *Clinical Pharmacology and Therapeutics*, 47: 204, 1990.
41. Gregoire, S., Winchell, G.A., Constanzer, M., Matuszerski, B. and **Lasseter, K.C.**: Multiple Dose Pharmacokinetics of Finasteride, a 5 alpha - reductase inhibitor in men 45-60 and ≥ 70 years old. (Presented at Annual Meeting of American Association of Pharmaceutical Scientists, Las Vegas, Nevada, November 6, 1990). *Pharmaceutical Research*, 7: S-53, 1990.
42. Nelson, E., Merrill, D., Sweet, C., Bradstreet, T., Panebianco, D., Byyny, R., Herman, T., **Lasseter, K.C.**, Levey, B., Lewis, G., McMahan, G., Reeves, R., Ruff, D., Sheppard, A., Weidler, D. and Irvin, J.: Efficacy and Safety of oral MK-954 (DUP 753), an angiotensin receptor antagonist, in essential hypertension. (Presented at 5th European Meeting on Hypertension, Milan, Italy, June 7-10, 1991). *J. European Society on Hypertension*, Abstract #512, 1991.
43. Gertz, B.J., Kline, W.F., Matuszewski, B.K., Sacco, J.F., **Lasseter, K.C.** and Porras, A.G.: Oral Bioavailability and Dose Proportionality of Alendronate (Aminohydroxybutylidene Bisphosphonate) in postmenopausal women. *J. Bone Mineral. Res.* 6:S281, 1991.
44. **Lasseter, K.C.**, Cevallos, W.H., Zimmerman, J., Conrad, K. and Chiang, S.T.: Ascending Single-Dose Tolerance and Pharmacokinetic Study of Celikalim (WAY-120-491) in Patients with Essential Hypertension. (Presented at 93rd Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March 18-20, 1992). *Clinical Pharmacology and Therapeutics*, 51:140, 1992.
45. Ford, N.F., **Lasseter, K.C.**, Hammet, J.L., VanHarken, D.R. and Wang-Iverson, D: Single-Dose and Steady-State Pharmacokinetics of Fosinopril in Patients with Hepatic Impairment. (Presented to the American Society of Hypertension). *Amer J. Hypertension*, 5:123A, 1992
46. Shamblen, E.C., **Lasseter, K.C.**, Lettieri, J., and Heller, A.: The Effect of Cirrhosis on the Steady-State Pharmacokinetics of Nifedipine Sustained Release Tablets. (Presented at 21st Annual Meeting of American College of Clinical Pharmacology, Washington, D.C., September 17-19, 1992). *J. Clinical Pharmacology*, 32:757, 1992.

ABSTRACTS (Continued)

47. S. Sainati, U. Shukla, P. Chaikin, R. Dockens and **K. C. Lasseter**: The Single and Multiple Dose Pharmacokinetics of Nefazodone in Healthy Volunteers and Subjects with Hepatic Impairment. (Presented at 21st Annual Meeting of American College of Clinical Pharmacology, Washington, D.C., September 17-19, 1992). *J. Clinical Pharmacology*, 32:756, 1992.
48. Schwartz, J., Laskin, O., Schneider, S., Seibold, J. and **Lasseter, K.C.**: Pharmacodynamics of a New 5-Alpha-Reductase Inhibitor (MK-0963): Effects on Serum Androgens. (Presented at 94th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Honolulu, Hawaii, March 24-26, 1993). *Clinical Pharmacology and Therapeutics*, 53:231, 1993.
49. Schwartz, J., Cheng, H., Pipkin, J., Larson, P., and **Lasseter, K.C.**: Comparison of Controlled-Release vs. Conventional Lovastatin Formulations. (Presented at 95th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, New Orleans, LA, March 30 - April 1, 1994). *Clinical Pharmacology and Therapeutics*, 55:187, 1994.
50. Shamblen, E.C., **Lasseter, K.C.**, Shamblen, S.C., Yeh, K.C., Ebel, D.L., Pinto, M.B., Panevianco, D., Han, R. and Schwartz, J.I.: Comparison of Famotidine Chewable vs. Film Coated Tablets. (Presented at the 23rd Annual Meeting of American College of Clinical Pharmacology, Orlando, FL, and October 6-8, 1994). *J. Clin. Pharmacol.* 34:1010 (7), 1994.
51. **Lasseter, K.C.**, Shamblen, E.C., Kringle, R., Lockwood, G. and Berger, B.M.: Steady State Pharmacokinetics (PK) of Danazol in Fed and Fasted Female Volunteers. (Presented at the 23rd Annual Meeting of American College of Clinical Pharmacology, Orlando, FL, October 6-8, 1994). *J.Clin. Pharmacol.* 34: 1010 (8), 1994.
52. Gertz, B.J., Wang, D., Ebel, D., Justice, S., **Lasseter, K.C.**, Schwartz, J.: Addition of a Type I 5alpha-Reductase Inhibitor to Finasteride may completely suppress circulating DHT in humans. (Presented to the Endocrine Society Meeting, Washington, D.C., June 1995).
53. Smith, D.A., Phillips, L., Fleck, R., Lasseter, **K.C.**, Shamblen, S.C. and Adam, K.: 311C90 in normotensive and mild-to moderate hypertensive volunteers: A Pharmacodynamic and Pharmacokinetic Comparison. (Presented at the International Headache Society Meeting, Toronto, Canada, Sept. 1995).
54. Brueckner, R., Coster, T., Wesche, D., Shmuklarsky, M., **Lasseter, K.C.** and Schuster, B.: Safety, Tolerance, Pharmacokinetics and Preliminary Antimalarial Efficacy of WR 238605 in Man. (Presented at the American Society of Tropical Medicine and Hygiene Meeting, 1995.).
55. Garg, D., **Lasseter, K.C.**, Shrotriya, R.C., Shamblen, E.C., Shamblen, S., Hoff, J. and Gallagher, S.C.: Pharmacokinetic Profile of pilocarpine hydrochloride in subjects with impaired hepatic function. (Presented at the 97th annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Orlando, Florida, March 20-22, 1996) *Clinical Pharmacology and Therapeutics* 59: 200, 1996.

ABSTRACTS (Continued)

56. Bekersky, I., Dressler, D., **Lasseter, K.C.** and Mekki, Q.: Effect of Mild Hepatic Dysfunction on the Pharmacokinetics of Tacrolimus. (Presented at the 15th Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May 27-30, 1996)
57. Marino, M.R., Langenbacher, K., Ford, N., Beierle, F., Shamblen, E.C. and **Lasseter, K.C.:** Effect of Hydrochlorothiazide on the Pharmacokinetics and Pharmacodynamics of Irbesartan. (Presented at the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, California, March 5-8, 1997). *Clinical Pharm. and Therap.* 61: 207, 1997.
58. Suttle, A.B., Vargo, D.L., Wilkinson, L., Birmingham, B. and **Lasseter, K.C.:** Effect of Zafirlukast on the Pharmacokinetics of R- and S- Warfarin in Healthy Men. (Presented at The 98th Annual meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, California, March 5-8, 1997). *Clinical Pharm. and Therap.* 61: 186, 1997.
59. **Lasseter, K.C.,** Marino, M.R., Langenbacher, K.M., Vesterqvist, O., Shamblen, E.C. and Ford, N.F.: Pharmacodynamics of Irbesartan in subjects with mild-to-moderate hypertension. (Presented at the 12th Scientific Meeting of the American Society of Hypertension, San Francisco, California, May 28-31, 1997) *The American Journal of Hypertension* 10: 121A, 1997.
60. Marino, M.R., Langenbacher, K.M., Raymond, R.H., Ford, N.F. and **Lasseter, K.C.:** Pharmacokinetics and Pharmacodynamics of Irbesartan in Subjects with Hepatic Cirrhosis. (Presented to the *1st International Symposium on Angiotensin II Antagonism* jointly sponsored by the British Hypertension Society and the International Society of Hypertension held at Kensington Town Hall, London, U.K., September 28th-October 1st, 1997).
61. **Lasseter, K.C.,** Marino, M.R., Langenbacher, K.M., Vesterqvist, O. Shamblen, E.C. and Ford, N.F.: Pharmacodynamics of Irbesartan in Subjects with Mild-to-Moderate Hypertension. (Presented to the *1st International Symposium on Angiotensin II Antagonism* jointly sponsored by the British Hypertension Society and the International Society of Hypertension held at Kensington Town Hall, London, U.K., September 28th October 1st, 1997).
62. Garg, V., Coward, T.D., Noorisa, M., **Lasseter, K.C.,** Dilzer, S.C. and Braner, S.: Effect of Hepatic Impairment on the Pharmacokinetics of Vesnarinone. (Presented to the Annual Scientific Meeting of the American Association of Pharmaceutical Scientists to be held in Boston, Mass., November 2-6, 1997). *Pharmaceutical Research* 14 (11Suppl): S508, 1997.
63. Marino, M.R., Langenbacher, K.M., Raymond, R.H., Ford, N.F., Dilzer, S.C. and **Lasseter, K.C.:** Pharmacokinetics and pharmacodynamics of irbesartan in Subjects with Hepatic Cirrhosis. (Presented to the 26th Annual Meeting of the American College of Clinical Pharmacology held in Phoenix, AZ, September 18th-20th, 1997). *J. Clin. Pharmacol.* 37: 871, 1997.

ABSTRACTS (Continued)

64. Vargo, D.L., Yeh, C., **Lasseter, K.C.**, Shamblen, E.C. and Birmingham, B.: Effect of Zafirlukast on Prothrombin Time and Area under the Curve of Warfarin. (Presented to the 26th Annual Meeting of the American College of Clinical Pharmacology held in Phoenix, AZ, September 18th - 20th, 1997). *J. Clin. Pharmacol.* 37: 870, 1997.
65. Suttle, A. B., Vargo, D.L., Wilkinson, L., Birmingham, B. and **Lasseter, K.C.**: Effect of Zafirlukast on the Pharmacokinetics of R- and S-Warfarin in Healthy Men. (Presented at the 1997 European Conference on Allergology and Clinical Immunology held in Rhodes, Greece, June 4th - 6th, 1997). *European J. Allergy and Clinical Immunology*.
66. Holland, S., Shahane, A., Grasing, K., **Lasseter, K.C.**, Pinto, M.B., Freeman, A. and Gertz, B.: The Metabolism of Montelukast (M) is increased following multiple doses of Phenobarbital. (Presented at the 99th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, New Orleans, LA, March 30th -April 1st, 1998) *Clinical Pharmacology and Therapeutics* 63: 231, 1998.
67. Sica, D., Zhou, W., **Lasseter, K.C.**, Lee, P and Pesco-Koplowitz, L.: Pharmacokinetics and safety of lubeluzole in subjects with hepatic impairment. (Presented to the ASHP Annual Meeting, June 1998).
68. Corey, A., Agnew, J., Comer, P.F., Dilzer, S.C., **Lasseter, K. C.**, Parekh, N., Powell, J., Valentine, S. and Thompson, G.A.: Effect of Hepatic Impairment on Azimilide Pharmacokinetics following Single Dose oral Administration. (Presented at the 1998 Annual Meeting of the American Association of Pharmaceutical Scientists in San Francisco, California November 15-19, 1998). *Pharm Sci* 1: S464, 1998.
69. Schwartz, J., Porras, A., Larson, P., Agrawal, N., Gumbs, C., Matthews, K., Woolf, E., Ebel, D., **Lasseter, K.C.** and Gertz, B.: Influence of Antacids on the Bioavailability (F) of a Specific Cyclooxygenase (COX)-2 Inhibitor, MK-0966 (M) in the Elderly. (Presented to the 100th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics held in San Antonio, Texas March 18th -20th, 1999). *Clinical Pharmacology and Therapeutics*, 65: 173, 1999.
70. Kalbag, J., Hirshberg, Y., McLeod, J., Garreffa, S. and **Lasseter, K.C.**: Comparison of Mealtime Glucose Regulation by Nateglinide and Repaglinide in Healthy Subjects. (Presented at the 59th Scientific Sessions of the American Diabetes Association in San Diego, California, June 18-22, 1999). *Diabetes* 48(Abstract Booklet): #0456, 1999.
- 71 Swan, S.K., **Lasseter, K.C.**, Ryan, C., Buechel, K.C., Lambrecht, L.J., Pinto, M.B., Dilzer, S.C., Obrda, O., Sundblad, K.J., Larson, P.J., Gertz, B.J., Brater, D.C. and Yao, S.L.: Renal effects of multiple-dose rofecoxib (R), a COX-2 inhibitor, in elderly subjects. (Presented at Annual Meeting of the American Society of Nephrology in Miami Beach, Florida November 7, 1999). *Journal of American Society of Nephrology Abstract* A3248, 1999.

ABSTRACTS (Continued)

72. Schwartz, J., Zhao, P., Gertz, B., Gumbs, C., Ebel, D., **Lasseter, K.** and Porras, A.: Pharmacokinetics of Rofecoxib in Mild to Moderate Hepatic Insufficiency (HI). (Presented at the 101st Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics in Los Angeles, CA, March 15-17, 2000) *Clinical Pharmacology and Therapeutics*, 67: 137, 2000.
73. Porras, A., Ko, A., Larson, P., Agrawal, N., Woolf, E., Ebel, D., **Lasseter, K.**, Gertz, B. and Schwartz, J.: Single and Multiple Dose Pharmacokinetics (PK) of Rofecoxib (R) in Healthy Subjects. (Presented at the 101st Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics in Los Angeles, CA, March 15-17, 2000) *Clinical Pharmacology and Therapeutics*, 67: 137, 2000.
74. Abrams, L. S., Skee, D., Natarajan, J., **Lasseter, K.C.** and Wong, F.: Dose Proportionality Study of a Contraceptive Patch. . (Presented at the 101st Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics in Los Angeles, CA, March 15-17, 2000). *Clinical Pharmacology and Therapeutics*, 67: 105, 2000.
75. Winchell, G., King, J. D., Korn, S.H., **Lasseter, K.**: Cyclobenzaprine Pharmacokinetics in the Elderly. (Presented at the 101st Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics in Los Angeles, CA, March 15-17, 2000). *Clinical Pharmacology and Therapeutics*, 67: 155, 2000.
76. Grim, C. E., Campese, V.M., Ferrario, C.M., **Lasseter, K.C.**, Ruddy, M.C., Vargas, R., Smith, W., Abdurahaman, A., Vesterqvist, O., Ge, Z., Delaney, C.L., Ditullio, L.J. and Liao, W.: Salt Sensitivity and Ethnic Variations: Renin-Angiotensin and Natriuretic Hormones. (Presented at the American Society of Hypertension 2000 Annual Meeting, New York, NY, May 15-18, 2000) *American Journal of Hypertension*, 13: 263A, 2000.
77. Campese, V.M., Ferrario, C.M., Ruddy, M.C., Grim, C.E., Smith, R.D., **Lasseter, K.C.**, Smith, W.B., Vargas, R., Habashy, M.F., Delaney, C.L., Ge, Z. and Liao, W.: Omapatrilat or Lisinopril in Salt-Sensitive Hypertensives. (Presented at the American Society of Hypertension 2000 Annual Meeting, New York, NY, May 15-18, 2000) *American Journal of Hypertension*, 13: 15A, 2000.
78. Vargas, R., Semiond, D., Sanderink, G., Noveck, R., McMahaon, F.G., **Lasseter, K.**, Gillen, M., Davidson, J., DePhillips, S. and Rao, Z.: An Open Label Study to Investigate the Pharmacokinetics (PK) of Ebastine in patients with Liver Impairment compared with Healthy Volunteers. (Presented at the 101st Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics in Los Angeles, CA, March 15-17, 2000). *Clinical Pharmacology and Therapeutics*, 67: 97, 2000.
79. Mazzu, A.L., **Lasseter, Kenneth C.**, Shamblen, E. Cooper, Agarwal, V. and Lettieri, John: Itraconazole alters the Pharmacokinetics of Atorvastatin to a greater extent than either Cerivastatin or Pravastatin. (Presented at the American College of Clinical Pharmacology 29th Annual Meeting in Chicago, Illinois, September 17-19, 2000), *J. Clin. Pharmacol* 40: 1049, 2000.

ABSTRACTS (Continued)

80. Abrams, L., Skee, D., Natarajan, J., Wong, F. and **Lasseter, K.C.**: Pharmacokinetics of multiple cycles of a contraceptive patch. (Presented at the American College of Clinical Pharmacology 29th Annual Meeting in Chicago, Illinois, September 17-19, 2000) *J. Clin Pharmacol* 40: 1047, 2000.
81. Schwartz, J. I., Larson, P.J., Gertz, B.J., Cote, J., **Lasseter, K.C.** and Porras, A.G.: Rofecoxib Steady-State Pharmacokinetics (PK) in Moderate Hepatic Insufficiency Patients (HI). Presented at VII World Conference of Clinical Pharmacology and Therapeutics (CPT-2000) at Florence, Italy July 15-20, 2000.
82. **Lasseter, K.C.**, Venitz, J., Eltahtawy, A., Miotto, J., Munera, C., Reder, R. and Reidenberg, B.E.: Systemic Pharmacokinetic (PK) Study of Buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). (Presented at the 102nd Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Orlando, Florida, March 6-10, 2001). *Clinical Pharmacology Therapeutics*, 69: 2P, 2001.
83. Porras, A.G., Kline, W., Dilzer, S., Holland, S., Freeman, A. and **Lasseter, K.C.**: Oral Bioavailability of alendronate 35- and 70-mg tablets. (Presented at the 102nd Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Orlando, Florida, March 6-10, 2001). *Clinical Pharmacology Therap.* 69: 84P, 2001.
84. Schwartz, J.I., Larson, P.J., Gertz, B.J., Cote, J., **Lasseter, K.** and Porras, A.G.: Steady-State Rofecoxib Pharmacokinetics (PK) in Moderate Hepatic Insufficiency Patients (HI). (Presented at the 102nd Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Orlando, Florida, March 6-10, 2001). *Clinical Pharmacology Therap.* 69: 60P, 2001.
85. Stone, J., Holland, S., Wickersham, P., Deutsch, P. Winchell, G., Miller, R., Freeman, A., Dilzer, S and **Lasseter, K.C.**: Drug Interactions Between Caspofungin and Tacrolimus. (Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois December 16-19, 2001). [Http://www.icaac.org/ICAAC.asp](http://www.icaac.org/ICAAC.asp)
86. Stone, J., Holland, S., Li, S., Wickersham, P., Deutsch, P. Winchell, G., Bi, S., Friel. M., Mistry, G., Dilzer, S and **Lasseter, K.C.**: Effect of Hepatic Insufficiency on the Pharmacokinetics of Caspofungin. (Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois December 16-19, 2001). [Http://www.icaac.org/ICAAC.asp](http://www.icaac.org/ICAAC.asp)
87. Schwartz, J., Malice, M., Kalyani, R., **Lasseter, K.**, Holmes, G., Gertz, B., Gottesdiener, K., Laurenzi, M. and Brune, K.: Effect of Rofecoxib, celecoxib and naproxen of Blood Pressure in elderly volunteers. (Presented at 16th Annual Scientific Meeting of the American Society of Hypertension, San Francisco, CA May 15th -19th, 2001) *American Journal of Hypertension* 14: 177A, 2001.

ABSTRACTS (Continued)

88. Schwartz, J.I., Malice, M.P., **Lasseter, K.C.**, Holmes, G.B., Gottesdiener, K. and Brune, K.: Effect of Rofecoxib, Celecoxib and Naproxen on Blood Pressure and Urinary Sodium Excretion. (Presented at EULAR 2001: Annual European Congress of Rheumatology, June 13-16, 2001, Prague, Czech Republic). Abstract No.: SAT0055. [Http://www.eular.org/eular2001/abstractsonline.cfm](http://www.eular.org/eular2001/abstractsonline.cfm).
89. **Lasseter, K.C.**, Venitz, J., Eltahtawy, A., Miotto, J., Munera, C., Reder, R. and Reidenberg, B.E.: Systemic Pharmacokinetic (PK) Study of Buprenorphine (B) in mild to moderate chronic hepatic impairment. (Presented at the 30th Annual Meeting of the American College of Clinical Pharmacology, Vienna, Virginia, September 23-25, 2001. Encore Abstract) *J. Clin. Pharmacol*, 41: 1028, 2001.
90. Thye, D., Kilfoil, T., White, R.J. and **Lasseter, K.**: Anidulafungin: Pharmacokinetics in Subjects with Mild and Moderate Hepatic Impairment. (Presented at the 41st InterScience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 12-16, 2001). [Http://www.icaac.org/ICAAC.asp](http://www.icaac.org/ICAAC.asp).
91. Guzzo, C., Furtek, C., Porras, A., Chen, C., Tipping, R., Clineschmidt, C. and **Lasseter, K. C.**: Safety, Tolerability and Pharmacokinetics of High-Dose Ivermectin (IVC) in Healthy Adults. (Presented at the 103rd Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 24-27th, 2002) *Clinical Pharmacology & Therapeutics*, 71: P50, 2002.
92. Agarwal, N.G., Matthews, C.Z., Rose, M.J., Woolf, E.J., Porras, A.G., Mazina, K., Farmer, J., Musser, B.J., Dynder, A.L., **Lasseter, K.C.**, Hunt, T.L., McCrea, J.B., Etoricoxib, a Highly Selective Inhibitor of Cyclooxygenase-2, in Healthy Subjects. (Presented at the 103rd Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 24-27th, 2002) *Clinical Pharmacology & Therapeutics*, 71: P50, 2002.
93. Agarwal, N.G., Geer, L.A., Cui, D., Halpin, R.A., Matthews, C.Z., Woolf, E.J., Porras, A.G., Larson, P.J., **Lasseter, K.C.**, Gottesdiener, K. and Rodrigues, A.D.: Disposition of [14-C] Etoricoxib in Healthy Subjects. (Presented at the 103rd Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 24-27th, 2002) *Clinical Pharmacology & Therapeutics*, 71: P49, 2002.
94. Schwartz, J.I., Malice, M., **Lasseter, K.C.**, Holmes, G., Gottesdiener, K., Gertz, B. and Brune, K.: Comparison of Rofecoxib, Celecoxib and Naproxen on Blood Pressure in Elderly Volunteers. (Presented at the 103rd Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 24-27th, 2002) *Clinical Pharmacology & Therapeutics*, 71: P7, 2002.

ABSTRACTS (Continued)

95. Mistry, G., Herman, G., Majumdar, P., Deutsch, P., Shamblen E.C. and **Lasseter, K.C.**: Single IV Doses of Ertapenem are not associated with clinically significant QTc prolongation. (Presented at the 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, Scotland, UK, May 10-13, 2003).
96. Bergman, A.J., Vega, J.M., Murphy, G., Burke, J., Prueksaritanont, T., Zhao, J., Valesky, R., Liu, L., Hartford, A., **Lasseter, K.**, and Rogers, J.: Simvastatin Does Not Have a Significant Pharmacokinetic Interaction with Fenofibrate in Humans. (Presentation at the American Heart Association Scientific Sessions 2002 in Chicago, IL November 17-20, 2002).
97. Stone, J., Holland, S., Hauck, W., Pequignot, E., Deutsch, P., Winchell, G., Hesney, M., Freeman, A., Bi, S., Dilzer, S. and **Lasseter, K.C.**: Drug Interactions between Caspofungin and Amphotericin B. (Submitted for Presentation at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14th -17th, 2003, Chicago, Illinois.).
98. Stone, J., Migoya, E., Hickey, L., Deutsch, P., Winchell, G., Freeman, A., Bi, S., Desai, R., Dilzer, S., **Lasseter, K.C.**, Kraft, W., Greenberg, H. and Waldman, S.: Drug Interactions between Caspofungin and Nelfinavir and Rifampin. (Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14th -17th, 2003, Chicago, Illinois.). [Http://www.abstractsonline.com](http://www.abstractsonline.com) Poster Session 160, A1605, 2003.
99. Schwartz, J.I., Larson, P.J., Porras, A. and **Lasseter, K.C.**: Evaluation of a Rofecoxib Suspension. (Presented at the 32nd Annual Meeting of the American College of Clinical Pharmacology, September 21st-23rd, 2003, Tampa, FL). *J. Clinical Pharmacology* 43: 1035, 2003.
100. Herman, G.A., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., **Lasseter, Kenneth C.**, Kipnes, M.S., Zhao, P., Hilliard, D., Tannen, M., DeLepeleire, I., Cilissen, C., Stevens, C., Tanaka, G., Gottesdiener, K. and Wagner, J.: The DPP-IV Inhibitor MK-0431 Enhances Active GLP-1 and reduces Glucose Following an OGTT in Type 2 Diabetes. (Presented at the American Diabetes Association, 2004 Annual Meeting.)
101. Schwartz, J., Vandormael, K., Thach, C., **Lasseter, K.C.**, Holmes, G.B., Miller, J. L., Hreniuk, D., Hilliard, D., Snyder, K.M., Gertz, B.J. and Gottesdiener, K.: Effect of Rofecoxib, Etoricoxib, Celecoxib and Naproxen on Urinary Excretion of Prostanoids in Elderly Volunteers. (Presented at 2004 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, March 24-27, 2004, Miami Beach, Florida) *Clinical Pharmacology & Therapeutics* 75: P34, 2004.
102. Rippley, R. K., Thach, C., Hreniuk, D., Miller, J. L., Yah, K., Song, H., **Lasseter, K. C.**, Gottesdiener, K. and Wagner, J. A.: Lack of Effect of Age and Gender on MK-0767 Pharmacokinetics in Healthy Subjects. (Presented at 2004 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, March 24-27, 2004, Miami Beach, Florida) *Clinical Pharmacology & Therapeutics* 75: P58, 2004.

ABSTRACTS (Continued)

103. Turncliff, R., Dunbar, J., Dong, Q., Oliva, J., **Lasseter, K. C.** and Silverman, B.: Single and Multiple Dose Pharmacokinetics of Extended Release Medisorb[®] Naltrexone. (Presented at the 2005 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, March 2-5, 2005, Orlando, Florida) *Clinical Pharmacology & Therapeutics*, 77: P42, 2005.
104. **Lasseter, Kenneth C.**, Morganroth, J., Schary, W., Adams, M.P., Fox, R. and DeWalt, P.: Cardiac Safety of a Novel MAO-B Inhibitor for the Treatment of Parkinson's Disease. (Presented at the 9th International Congress of Parkinson's Disease and Movement Disorders. New Orleans, La., March 5-8, 2005.
105. **Lasseter, Kenneth C.**, Morganroth, J., Schary, W., Adams, M.P., Fox, R, DeWalt, P.: Cardiac Safety of a novel selective MAO-B inhibitor for Parkinson's Disease (Submitted for presentation at the American Neurological Assn 130th Annual Meeting. San Diego, CA. September, 2005.
106. Bergman, A., Krishna,R., Ebel, D., Liu, F., Stone, J., Wang, A., Zeng, W., Chen, L., Dilzer, S. **Lasseter, K.C.**, Wagner, J., Herman, G.: Lack of a Pharmacokinetic Food Effect and Evaluation of the Definitive Bioavailability of Sitagliptin (MK-0431), an Oral Dipeptidyl Peptidase IV Inhibitor. (Presented at the American College of Clinical Pharmacology, 34th Annual Meeting, September 11-13th, 2005 in Rockville, Maryland). *J Clin Pharmacology* 45: 1089, 2005. .
107. Bergman, A., Krishna, R., Mistry, G., Luo, W., Liu, Q., Stone, J., Wang, A., Zeng, W., Chen, L., Dilzer, S., **Lasseter, K.C.**, Wagner, J. and Herman, G.: Dose-Proportionality of Sitagliptin (MK-0431), an Oral Dipeptidyl Peptidase IV Inhibitor in Healthy Volunteers. (Presented at the American College of Clinical Pharmacology, 34th Annual Meeting, September 11-13th, 2005 in Rockville, Maryland). *J Clin. Pharmacology* 45: 1090, 2005.
108. Vincent, S., Reed, J.R., Bergman, A., Zhu, B., Xu, S., Ebel, D., Larson, P., Wang, A., Zeng, W., Chen, L., Musson, D., Schenk, D., Elmore, C., Marques, R., **Lasseter, K.C.**, Gottesdiener, K., Wagner, J. and Herman, G.: Metabolism and Excretion of the DPP-IV Inhibitor [¹⁴C] Sitagliptin (MK-0431) in Humans. (Presented at the American College of Clinical Pharmacology, 34th Annual Meeting, September 11-13th, 2005 in Rockville, Maryland). *J Clin. Pharmacology* 45: 1088, 2005.
109. Poola, N., Kashanian, F., **Lasseter, K.C.** and Dandekar, K.: Pharmacokinetics and Safety of Gd-DTPA after Single Bolus Intravenous Dose of Magnevist[®] in Subjects with Moderate Hepatic Impairment and in Healthy Male, Female and in Elderly Subjects. (Presented at the American Association of Pharmaceutical Scientists annual meeting, Nashville, TN (Nov 6 - 10, 2005).

ABSTRACTS (Continued)

110. Stevens, C., Bergman, A., Liu, Q., Luo, W., Wang, A., Zeng, W., **Lasseter, K. C.**, Dilzer, S., Wagner, J., Herman, G. and Migoya, E.: Lack of Clinically Significant Effect of Moderate Hepatic Insufficiency on the Pharmacokinetics of MK-0431 (Sitagliptin), a Dipeptidyl-Peptidase-IV (DPP-IV) Inhibitor. (Presented at 2006 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, March 7-11, 2006, Baltimore, Md). *Clinical Pharmacology & Therapeutics*, 79: P49, 2006.
111. Wright, D.H., Maes, A., Yi, B., Bergman, A., Liu, Q., **Lasseter, Kenneth C.**, Gottesdiener, K.M., Wagner, J.A. and Herman, Gary: Multiple Dose Administration of MK-0431 (Sitagliptin), an Inhibitor of Dipeptidyl Peptidase-IV, does not Meaningfully alter the Plasma Pharmacokinetics or Pharmacodynamics of Single Doses of Warfarin. (Presented at 2006 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, March 7-11, 2006, Baltimore, Md). *Clinical Pharmacology & Therapeutics*, 79: P76, 2006.
112. Krishna, R., Bergman, A., Larson, P., Cote, J., **Lasseter, K. C.**, Pierre, M., Wang, A., Zeng, W., Chen, L., Wagner, J. and Herman, G.: Effect of a single Cyclosporin A (Neoral™) Dose on the Pharmacokinetics (PK) of Sitagliptin (MK-0431), a Dipeptidyl Peptidase IV Inhibitor (DPP-IV) in Healthy Male Subjects. . (Presented at 2006 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, March 7-11, 2006, Baltimore, Md). *Clinical Pharmacology & Therapeutics*, 79: P63, 2006.
113. Petry, A.S., Wenning, L.A., Laethem, T., De Smet, M., Kost, J.T., Merschman, S., Ramael, S., **Lasseter, K.C.**, Gottesdiener, K.M., Wagner, J.A. and Iwamoto, M.: Safety, Tolerability and Pharmacokinetics after Single- and Multiple-Doses of MK-0518 in Healthy Subjects. (Presented at the 46th Annual ICAAC, September 27-30, 2006, San Francisco, CA).
<http://www.icaac.org/acceptedabstracts3.asp>
114. Wenning, L., Hanley, W., Friedman, E., Moreau, A., Kost, J., Merschman, S., Mangin, E., **Lasseter, K.C.**, Shamp, T., Gottesdiener, K.M., Wagner, J. and Iwamoto, M.: Drug Interactions of MK-0518 with Tenofovir Disoproxil Fumarate and with Tipranavir + Ritonavir. (Presented at the 46th Annual ICAAC, September 27-30, 2006, San Francisco, CA).
<http://www.icaac.org/acceptedabstracts3.asp>.
115. Kassahum, K., McIntosh, I., Merschman, M., Iwamoto, M., Hreniuk, D., Wagner, J.A., **Lasseter, K.C.** and Wenning, L.: Absorption, Metabolism and Excretion of MK-0518, a potent HIV-1 Integrase Inhibitor in Healthy Male Volunteers. (Presented at the 46th Annual ICAAC, September 27-30, 2006, San Francisco, CA).
<http://www.icaac.org/acceptedabstracts3.asp>
116. Ramakrishnan, R., Cerchio, K., Talaty, J., Gargano, C., Rippley, R., **Lasseter, K.**, Murphy, M.G. and Alexander, R.: Gaboxadol Does Not Affect the Single Dose Pharmacokinetics of the R(+) and S(-) Enantiomers of Warfarin and the Pharmacodynamics of Warfarin. (Submitted for Presentation at the APSS 20th Annual Meeting, June 17-20, 2006, Salt Lake City, Utah). *Sleep*, In Press, 2006.

ABSTRACTS (Continued)

117. Wolford, D., Ming, J., Ramakrishnan, R., Luo, R., Fu, I., Gargano, C., Rippley, R., **Lasseter, K.**, Murphy, G. and Alexander, R.: Gaboxadol Does not Require a Dose Adjustment on the basis of Hepatic Insufficiency. (Submitted for Presentation at the APSS 20th Annual Meeting, June 17-20, 2006, Salt Lake City, Utah). *Sleep*, In Press, 2006.
118. Schwartz, J.I., Stroh, M., Liu, F., Gipson, A., Wenning, L., **Lasseter, K.C.** and Wagner, J.A.: The Effect of MK-0524 (DP Receptor Antagonist) on the Pharmacokinetics and Pharmacodynamics of Warfarin. (Presented at 2007 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, March 21-24, 2007, Anaheim, CA). *Clinical Pharmacology & Therapeutics*. 81: S82, 2007.
119. Friedman, E. J., Hanley, W. D., Kost, J. T., Zajic, S., Merschman, S. A., **Lasseter, K. C.**, Wenning, L. A., Stone, J. A., Wagner, J. A. and Iwamoto, M.: Effect of Moderate Hepatic Insufficiency (HI) on Raltegravir (RAL) Pharmacokinetics (PK). (Presented at the 47th Annual ICAAC, September 17-20, 2007, Chicago, IL).
120. Schwartz, Jules I., Yuan, Jinyu, Li, Susie, Miller, Deborah L., Rosko, Kim, Zakson, Michelle, **Lasseter, Kenneth C.** and Wagner, John A.: Influence of Taranabant, a Novel Cannabinoid-1 Receptor (CB-1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Pharmacokinetics. (Presented at the NAASO Annual Scientific Meeting, New Orleans, LA, October, 20-24, 2007). *Obesity(Abtract Supplement 9/07)* 15: 268-P, 2007.
121. Schwartz, Jules I., Yuan, Jinyu, Li, Susie, Miller, Deborah L., Rosko, Kim, Zakson, Michelle, **Lasseter, Kenneth C.** and Wagner, John A.: Influence of Taranabant, a Novel Cannabinoid-1 Receptor (CB-1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Pharmacokinetics. (Presented at the American College of Clinical Pharmacology 36th Annual Scientific Meeting, San Francisco, CA, September 9-11, 2007). *J Clin Pharmacol* 47: 1192, 2007.
122. Addy, Carol, Cote, Josee, Li, Susie, Li, Hankun, Yuan, Jinyu, Dunbar, Stephanie, **Lasseter, Kenneth C.**, Stoch, Aubrey, Gottsdiener, Keith and Wagner, John: Taranabant Plasma Concentrations Increased When Co-administered with Ketoconazole or Diltiazem. (Presented at the NAASO Annual Scientific Meeting, New Orleans, LA, October 20-24, 2007). *Obesity (Abstract Supplement 9/07)* 15: 472-P, 2007.
123. Bergman, A., Dykstra, K., Al-Huniti, N., Fallon, M., Lutz, R., Chavez-Eng, C., Jin, B., Hartford, A., Cote, J., Hilliard, D., Laethem, T., Van Hoydonck, P., Snyder, K., Van Dyck, K., Stone, J., **Lasseter, K. C.**, Van Bortel, L., Wagner, J. and Krishna, R.: Optimizing dose selection using population PK/PD modeling and simulation for the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib (MK-0859) in healthy subjects. (Presented at the AAPS Annual Meeting and Exposition, November 11-15, 2007, San Diego, CA).

ABSTRACTS (Continued)

124. **Lasseter, Kenneth C.**, Aubets, J. and Garcia-Gil, E.: Aclidinium Bromide, a novel long-acting anticholinergic, does not affect QT interval in healthy subjects. (Presented at the American Thoracic Society Meeting in Toronto, ON, Canada, May 16-21, 2008). Amer. Journal of Respiratory and Critical Care Medicine 177: A655, 2008.
125. Schwartz, J., Yuan, J., Li, S., Gipson, A., Rosko, K., Zakson, M., **Lasseter, Kenneth C.** and Wagner, J.: Influence Of Taranabant, A Novel Cannabinoid 1 Receptor (Cb-1r) Inverse Agonist, on The Pharmacokinetics and Pharmacodynamics of Warfarin. (Presented at 2008 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, April 2-5, 2008, Orlando, FL). Clinical Pharmacology & Therapeutics 83(Suppl 1): S22, 2008.
126. Peeters, P. A., Bockbrader, H., Spaans, E., **Lasseter, K.**, Marbury, T. and deGreef, R.: Influence of Hepatic Impairment on Asenapine Pharmacokinetics. (Presented at 2008 Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, April 2-5, 2008, Orlando, FL). Clinical Pharmacology & Therapeutics 83(Suppl 1): S23, 2008.
127. Hompesch, M., **Lasseter, Kenneth C.**, Schwartz, S., Smedegaard, J., Hang, Y. and Lyness, William: Stepwise Basal Insulin Titration Using Continuous Subcutaneous Insulin Infusion in Type 2 Diabetes Mellitus Subjects Followed by Out-Patient Maintenance Phase. (Submitted for presentation to the ADA 2008 Meeting, June 6-10, 2008 in San Francisco, CA).
128. Garcia Gil, E., **Lasseter, K.** and Aubets, J.: Aclidinium bromide, a novel long-acting anticholinergic, does not affect QT interval in healthy subjects. (Presented at the European Respiratory Society Annual Congress 2008, October 4-8, 2008, Berlin, Germany).
129. Hompesch, M., Schwartz, S., Smedegaard, J. S., Lyness, W., Hang, Y. and **Lasseter, Kenneth:** Substantial Improvement in Glycaemic Control after Stepwise Basal Titration Using Continuous Subcutaneous Insulin Infusion Followed by Maintenance Phase in Subjects with T2DM. (Presented to the European Association for the Study of Diabetes (EASD) 2008 Meeting, September 7-11, 2008, Rome, Italy).
130. Haffey, M., Buckwalter, M., Zhang, P., Homolka, R., Martin, P., **Lasseter, Kenneth C.** and Ermer, J.: Effects of Omeprazole on the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Extended-Release Mixed Amphetamine Salts in Adults. (Presented at the American College of Clinical Pharmacy Meeting, April 24-28, 2009, Orlando, FL.)